Recent Forum Posts &
Article Comments

  • Comments
  • Forum Posts
  • Susan Mandel: Mark, your article takes me back to my pre-menopause days of pregnancy tests twice a month in order...
  • Lu Olson: Thank you for your article, Mark. I have experienced the same trials with ordering my Revlimid. I've been...
  • Diana Barker: Hello Nancy, I am always happy to read your articles, because I also live in Canada (southern...
  • Patty Muckala: Thank you, Nancy, for another wonderful column. Your Dilip sounds like a real gem. I, too, don’t...
  • Nancy shamanna: Thanks Christina for this heartfelt comment. I am wishing you and your husband all the best as you...
  • Mike F: Geez, that didn't take long. I hope that getting back on the Darzalex knocks those numbers right back down again!...
  • Ron Harvot: Sounds like you are doing great! Not much of a change given the treatment holiday. Ron...
  • Pepperink: Month 25, 26, 27/28: Darzalex Infusions #38, 39, 40 (monthly) To recap a bit: At diagnosis I was “stage 4,” with 90% my...
  • Mike F: It really is interesting that your blood work continues to show improvement. Great news, though, and another month off o...
  • Nancy Shamanna: Thanks for sharing your recent results, Victor. It is interesting that the myeloma markers show improvement despite you ...
  • Click here for more activity.

Recent Forum Discussions -
Highlights

  • Lori's intro­duction: plasmacytoma & high-risk disease at age 42
  • Victor's experience with Kyprolis, Pomalyst & dex
  • Pepperink’s (ongoing) Darzalex treatment journal
  • Diana's CAR T-cell therapy journey
  • Steve's update after his second stem cell transplant
  • Best time of day to take myeloma treatments?
  • Evenity for myeloma-related bone issues?
  • Venclexta & nasal congestion
  • Dating when you have multiple myeloma
  • Darzalex and diverticulitis

Forum Discussions -
View By Specific Subject

  • Treatments - Revlimid, Velcade, thalido­mide, Pomalyst, Kyprolis, Darzalex, Ninlaro, Empliciti, cyclo­phos­phamide, mel­phalan, dexa­metha­sone, prednisone, RVD / VRD, CyBorD / VCD
  • Side Effects - Blood clots / deep vein thrombosis, cramps / cramping, gastro­intestinal issues, fatigue, pain, peripheral neuropathy, rash / itching
  • Other Topics - M-spike, kappa / lambda free light chain testing & myeloma, stem cell trans­plan­ta­tion (generally), main­tenance therapy, allo (donor) stem cell trans­plants
  • More Treatment- And Side Effect-Related Subects

Myeloma-Related
Press Releases (Selection)

  • [Oct 1] Melflufen Expanded Access Program Now Open To Eligible U.S. Myeloma Patients
  • [Sep 22] Ide-Cel (bb2121) New Drug Appli­ca­tion Accepted By U.S. FDA & Granted Priority Review
  • [Sep 9] PBCAR269A Granted Fast Track Des­ig­na­tion By U.S. FDA
  • [Sep 8] KP1237 Granted Orphan Drug Des­ig­na­tion In Multiple Myeloma By U.S. FDA
  • [Aug 29] U.S. FDA Grants Pri­or­ity Re­view To Mel­flufen New Drug Appli­ca­tion
  • [Aug 26] European Commission Approves Blenrep (Belanta­mab Mafo­dotin) As New Treat­ment Op­tion For Re­lapsed Multiple Myeloma
  • [Aug 20] U.S. FDA Approves Darzalex-Kyprolis-Dex Regimen For Re­lapsed Multiple Myeloma
  • [Aug 5] U.S. FDA Approves Blenrep (Belanta­mab Mafo­dotin) As New Treat­ment Op­tion For Re­lapsed Multiple Myeloma
  • [Aug 3] First Patient Dosed in Phase 1b/2a Clinical Trial Of Tas­quini­mod In Relapsed Myeloma
  • [Jul 20] U.S. FDA Accepts For Review Appli­ca­tion To Approve Second-Line Use Of Xpovio
  • [Jul 14] U.S. FDA Gives Go-Ahead For First Clinical Trial Of Allo­geneic CAR T-Cell Therapy CYAD-211
  • [Jul 6] Clinical Trial Of UCARTCS1A, A Poten­tial New Myeloma Ther­apy, Placed On Hold Due To Patient Death
  • [Jun 22] First Patient Dosed In Phase 1b Clin­ical Trial Of Niro­gacestat & Belantamab Mafodotin (GSK2857916) In Relapsed Myeloma
  • [Jun 4] European Commission Approves Sub­cu­ta­neous Formu­la­tion Of Darzalex For The Treat­ment Of Multiple Myeloma
  • [Jun 2] Sarclisa (Isatuximab) In Combi­nation With Pomalyst & Dex Approved In Europe As New Treat­ment For Relapsed Myeloma
  • [May 22] European Medicines Agency (EMA) Accepts For Review Ide-Cel (bb2121) Appli­ca­tion For Approval
  • [May 1] U.S. FDA Approves Darzalex Faspro For The Treat­ment Of Multiple Myeloma
  • [Mar 10] Addition of Ninlaro To Revlimid & Dex Yields Not-Quite-Statistically-Significant Improvement In Progression-Free Survival In Newly Diagnosed Myeloma Patients
  • [Mar 9] Addition Of Empliciti To Revlimid & Dex Fails To Improve Progression-Free Survival In Newly Diagnosed Myeloma Patients
  • [Mar 2] U.S. FDA Approves Sarclisa (Isatuximab-irfc) In Combination With Pomalyst & Dex As New Treatment For Relapsed Myeloma
  • All myeloma-related press releases at The Beacon

News

  • Popular
  • Recent
  • Solitary Bone Plasmacytoma – What Every Patient Should Know
  • Understanding Prognosis In Multiple Myeloma
  • Bone Lesions Detected By MRI Can Predict Progression Of Smoldering Myeloma
  • Multiple Myeloma Survival Increased Significantly The Past 15 Years, But Unevenly Across Ethnic And Age Groups
  • New Criteria For The Diagnosis Of Multiple Myeloma And Related Disorders
  • Importance Of Factors Affecting Multiple Myeloma Survival Changes With Patient Age
  • Darzalex May Affect Different Uninvolved Immunoglobulins Differently
  • Getting To Know: Tiragolumab
  • Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
  • Lather, Rinse, Repeat: Will It Work With BCMA-Targeted Therapies For Multiple Myeloma?

Resources

  • Popular
  • Recent
  • Multiple Myeloma-Associated Amyloidosis – What Every Patient Should Know
  • Guide To Nutrition In Multiple Myeloma – Part 2: Supplements
  • Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence
  • Revlimid
  • Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
  • Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression
  • Psychiatric Comorbidities Are Associated with Increased Cost of Care and Healthcare Utilization in Multiple Myeloma (MM) Patients
  • Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation
  • Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial)
  • Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available MMRF Commpass Study Database

Subscribe

  • Get Beacon News by Email
  • Get Forum posts by Email
  • Follow us on Facebook
  • Follow us on LinkedIn
  • Follow us on Twitter
  • Subscribe to our News RSS feed
  • Subscribe to our Forum RSS feed

News Archives

  • ►2019 (12)
    • ► November (1)
      • Importance Of Factors Affecting Multiple Myeloma Survival Changes With Patient Age
    • ► October (2)
      • Darzalex May Affect Different Uninvolved Immunoglobulins Differently
      • Getting To Know: Tiragolumab
    • ► September (2)
      • Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
      • Lather, Rinse, Repeat: Will It Work With BCMA-Targeted Therapies For Multiple Myeloma?
    • ► August (2)
      • Getting To Know: TNB-383B
      • Number And Type Of Stem Cell Transplants Carried Out Each Year For Multiple Myeloma Vary Markedly Across U.S. Cancer Centers
    • ► May (3)
      • Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
      • Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
      • Early Use Of Radiation Therapy Associated With Shorter Survival In Multiple Myeloma
    • ► April (2)
      • ECT-001 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation By U.S. FDA
      • U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
  • ►2018 (23)
    • ► November (3)
      • Diet May Affect Risk Of Developing MGUS And Risk Of MGUS Progressing To Multiple Myeloma
      • Revlimid, Velcade, and Dexamethasone, Followed By Stem Cell Transplantation, Yields Deep Responses And Considerable Overall Survival In Newly Diagnosed Multiple Myeloma
      • Sustained Complete Response To Initial Treatment Associated With Substantial Survival Benefit In Multiple Myeloma
    • ► October (7)
      • Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
      • Stem Cell Transplantation May Be Underutilized In Multiple Myeloma Patients In Their 80s
      • Dr. Craig Hofmeister On Testosterone And Multiple Myeloma
      • Recently Diagnosed Myeloma Patients Very Likely To Have Low Testosterone Levels, Study Finds
      • Researchers Shed More Light On Risk Of MGUS In Close Relatives Of People With Multiple Myeloma
      • FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
      • Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
    • ► September (2)
      • Adding Clarithromycin To Velcade-Based Myeloma Treatment Regimen Fails To Increase Efficacy While Markedly Increasing Side Effects
      • Selective Digestive Decontamination May Reduce Risk of Infection In Myeloma Patients Undergoing Autologous Stem Cell Transplants
    • ► June (4)
      • Once-Weekly High-Dose Kyprolis Yields Deeper Responses And Longer Remissions Than Twice-Weekly Kyprolis (ASCO & EHA 2018)
      • Could A Decades-Old Antibiotic Have Anti-Myeloma Activity?
      • bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
      • ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
    • ► May (4)
      • Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
      • Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
      • Researchers Find No Disease Progression, And Frequent Disease Disappearance, In Study Of Light Chain MGUS
      • New Trial Results Reinforce Expectations For Selinexor In Myeloma; Application For FDA Approval To Be Filed Later This Year
    • ► April (3)
      • Faster Darzalex Infusions Can Be Safe, Study Says
      • Gradual Response To Initial Treatment May Be Sign Of Better Prognosis In Multiple Myeloma
      • Key U.S. Multiple Myeloma Survival Rate Unchanged In Annual Cancer Statistics Update
  • ►2016 (54)
    • ► June (5)
      • ASCO 2016 Multiple Myeloma Update – Poster Presentations: Current Myeloma Therapies & Smoldering Myeloma
      • ASCO 2016 Multiple Myeloma Update – Days Four & Five – Potential New Myeloma Therapies
      • ASCO 2016 Multiple Myeloma Update – Days One, Two, And Three
      • Myeloma Morning: Pomalyst, Compassionate Use, And Umbilical Cord Blood Transplants
      • Pomalyst and Dexamethasone For Heavily Pretreated Multiple Myeloma: New Results From Large Trial In Line With Results Of Previous Trials
    • ► May (11)
      • Myeloma Morning: Early Relapse And Survival, And Ninlaro & Kyprolis In Europe
      • Darzalex Approved In Europe
      • Myeloma Morning: Transplants In Patients With Kidney Impairment And In Older Patients
      • Myeloma Morning: Important New Transplantation And Darzalex Trial Results, And More
      • Myeloma Morning: Survival & Age, Once-Weekly Kyprolis, And Revlimid & Neutropenia
      • Myeloma Morning: A T(11;14) Deep Dive, And Subcutaneous Fat & Overall Survival
      • Empliciti Approved In Europe
      • Myeloma Morning: Velcade And Eyelid Inflammations, Imaging, And Race & Weight
      • Myeloma Morning: Darzalex & YM155, The Sendai Virus, And Argonaute 2
      • Myeloma Morning: Bence Jones Protein & Smoldering Multiple Myeloma, Plasma Cell Percentage Measurement, And TJP1
      • Myeloma Morning: Minimal Residual Disease, And BCMA & APRIL In Multiple Myeloma
    • ► April (27)
      • Myeloma Morning: Allogeneic Stem Cell Transplantation In Europe
      • Myeloma Morning: Marizomib, And Bone Cell Precursors As Possible Disease Markers
      • Key Ninlaro Clinical Trial Results Published
      • Myeloma Morning (Acronym Edition) - MMSET, IGF, SPEP, And EBMT 2016 (Part 1)
      • Myeloma Morning: Monoclonal Gammopathy Of Renal Significance (MGRS)
      • Myeloma Morning: The Abscopal Effect, And The Demographics Of Clinical Trial Participants
      • Myeloma Morning: Important New Darzalex Results, And More On Treanda In Transplantation
      • Myeloma Morning: ASCO 2016 Multiple Myeloma Poster Presentation Titles
      • Myeloma Morning: ASCO 2016 Multiple Myeloma Oral Presentation Titles
      • Myeloma Morning: Empliciti, Velcade, And Dexamethasone; And Treanda
      • Myeloma Morning: Personalizing Multiple Myeloma Therapy, And Lansoprazole (Round 2)
      • Myeloma Morning: Lansoprazole (Prevacid), And Saracatinib For Myeloma Bone Disease
      • Myeloma Morning: More People With Multiple Myeloma, MGUS Survival, And Dopamine
      • Myeloma Morning: New Multiple Myeloma Survival Data, Pomalyst & Kidneys, And MGUS
      • Myeloma Morning: Early Mortality In Newly Diagnosed Multiple Myeloma Patients
      • Myeloma Morning: It's Quiet, And CCF642 & PDI Inhibition
      • Myeloma Morning: Post-Transplant Outcomes, Soliris For TMA, And A Bit More On CCF642
      • Myeloma Morning: Revlimid In Patients With Kidney Damage, And Velcade Retreatment
      • Myeloma Morning: Genetics And Velcade-Related Peripheral Neuropathy
      • Myeloma Morning: Kyprolis And Immunotherapy Targets, And A PET/CT Reminder
      • Myeloma Morning: CCF642, BDA-366, And Putting Payloads On Platelets
      • Myeloma Morning: Myeloma Cells In Stem Cell Reinfusions, And Cytoxan And Mobilization
      • Myeloma Morning: Allogeneic Transplantation, And Nuances In The Treatment Of Older Patients
      • Myeloma Morning: MorphoSys Sues, Claims Darzalex Infringes Patent; And CUDC-907
      • Myeloma Morning: B Cells And Multiple Myeloma, And GEP Risk Signature Translation
      • Myeloma Morning: Treating Relapsed Multiple Myeloma, And Second Primary Malignancies
      • Myeloma Morning: Darzalex Closer To European Approval, And Allogeneic Transplantation
    • ► March (9)
      • Myeloma Morning: Positive Darzalex & Aplidin Trial Results, And The FDA Approves Defitelio
      • Myeloma Morning: Cometriq, And More On Kyprolis And Thrombotic Microangiopathy
      • Myeloma Morning: Pomalyst & Kidney Impairment, And Treatment & Heavy/Light Chain Levels
      • Myeloma Morning: Kyprolis And Thrombotic Microangiopathy, Roneparstat, And SPRY2
      • Myeloma Morning: New Proteasome Inhibitors, And More On MGUS & Smoldering Progression
      • Myeloma Morning: MGUS And Smoldering Myeloma Progression, And Dialysis Independence
      • Myeloma Morning: Extramedullary Disease Case Reports, And Zarxio vs. Neupogen
      • Myeloma Morning: IMWG Consensus On High-Risk Cytogenetics, VTD vs. VCD, And Marizomib
      • Myeloma Morning: Nexavar, MIG, Addressing Spinal Damage, And ... Mangos
    • ► February (1)
      • Remembering Pat Killingsworth
    • ► January (1)
      • The Myeloma Quiz – January 2016
  • ►2015 (26)
    • ► December (1)
      • Empliciti (Elotuzumab) Approved By FDA For Multiple Myeloma
    • ► November (3)
      • Ninlaro (Ixazomib) Approved By FDA For Multiple Myeloma
      • Kyprolis Approved In Europe
      • Darzalex (Daratumumab) Approved By FDA For Multiple Myeloma
    • ► July (3)
      • The Myeloma Quiz – July 2015
      • Elotuzumab – A Closer Look At The ELOQUENT-2 Clinical Trial Results
      • Daratumumab Expanded Access Program Initiated
    • ► June (6)
      • Farydak Gets Positive Opinion From European Advisory Committee; Approval Expected Within Three Months
      • Multiple Myeloma Highlights From The 2015 ASCO, EHA, And IMWG Annual Summit Meetings
      • ASCO 2015 Multiple Myeloma Update – Poster Presentations: Potential New Myeloma Therapies
      • Daratumumab FDA Application And Review Process Starts
      • CAR T-Cell Therapy For Multiple Myeloma: Promising Signs Of Efficacy (ASCO 2015)
      • ASCO 2015 Multiple Myeloma Update – Poster Presentations: Current Therapies; Impact Of Del(17p) And T(11;14)
    • ► May (2)
      • Daratumumab Continues To Show Substantial Promise As Potential New Treatment For Multiple Myeloma (ASCO 2015)
      • Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2015)
    • ► April (2)
      • Subcutaneous Velcade Leads To Similar Response Rates, But Fewer Side Effects, Compared To IV Velcade In Newly Diagnosed Multiple Myeloma
      • Combination Of Farydak And High-Dose Kyprolis Effective In Relapsed Multiple Myeloma
    • ► March (4)
      • Survival Of Nonsecretory Multiple Myeloma Patients Improves Over Last Decade
      • Additional Treatment To Deepen Response Prior To Transplantation May Not Improve Survival In Newly Diagnosed Multiple Myeloma
      • Common Chromosomal Abnormalities Occur Less Often In African-American Than White Multiple Myeloma Patients
      • High-Dose Kyprolis Extends Progression-Free Survival Versus Velcade In Head-To-Head Relapsed Myeloma Trial
    • ► February (4)
      • Farydak – Questions & Answers About The FDA Approval
      • FDA Approves Farydak (Panobinostat) For The Treatment Of Relapsed Multiple Myeloma
      • FDA Broadens Revlimid's Approved Use To Include Newly Diagnosed Multiple Myeloma
      • Ixazomib Succeeds In Key Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Expected Later This Year
    • ► January (1)
      • The Myeloma Quiz – January 2015
  • ►2014 (62)
    • ► December (4)
      • ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session
      • ASH 2014 Multiple Myeloma Update – Day One: Poster Session
      • ASH 2014 Multiple Myeloma Update - Day One: Oral Sessions
      • ASH 2014 Preview: New Multiple Myeloma Treatments On The Horizon
    • ► November (6)
      • FDA Postpones Decision On Panobinostat Approval Application
      • Panobinostat Fails In Bid For FDA Advisory Committee Support
      • Live Coverage Of The Panobinostat FDA Advisory Committee Meeting
      • Panobinostat’s FDA Advisory Committee Meeting May Be A Bit Tougher Than Expected
      • FDA Releases Key Documents Related To Panobinostat Advisory Committee Meeting
      • Evolution, Intra-Clonal Heterogeneity, And Multiple Myeloma
    • ► October (4)
      • New Criteria For The Diagnosis Of Multiple Myeloma And Related Disorders
      • British Researchers Document Potential Solution For Revlimid Gastrointestinal Side Effect
      • Panobinostat FDA Review On Schedule, Novartis Says
      • FDA Delays Decision On Panobinostat New Drug Application
    • ► September (1)
      • Dyclonine, The Active Ingredient In Sucrets, May Enhance The Anti-Myeloma Activity Of Velcade
    • ► August (6)
      • OncoPep Begins Sponsorship Of The Myeloma Beacon
      • MRI Of The Spine Identifies Smoldering Myeloma Patients At High Risk Of Progressing To Multiple Myeloma
      • Kyprolis Fails To Provide Overall Survival Benefit In FOCUS Phase 3 Trial
      • Remembering Stephen Kramer
      • CPI-0610 To Be Tested As Potential Multiple Myeloma Therapy
      • Kyprolis Succeeds In Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Planned For Europe And Other Countries
    • ► July (4)
      • Remembering Arnold Goodman
      • The Myeloma Quiz – July 2014
      • Treatment Regimen Featuring Revlimid-Velcade-Dexamethasone Therapy And Stem Cell Transplantation Yields Deep Responses In Newly Diagnosed Multiple Myeloma
      • The Neglected Common Thread: Malaria Drugs As Potential Myeloma Therapies
    • ► June (5)
      • Highlights Of The 2014 International Myeloma Working Group Annual Summit
      • ASCO 2014 Multiple Myeloma Update – Day Four: Poster Presentations
      • Array BioPharma Initiates Sponsorship Of The Myeloma Beacon
      • ASCO 2014 Multiple Myeloma Update – Day Four: Oral Presentations
      • Novartis Submits Panobinostat For FDA Approval As New Treatment For Multiple Myeloma, Gains Priority Review
    • ► May (6)
      • ASCO 2014 Multiple Myeloma Update – Day One
      • The Myeloma Beacon’s Medical Advisor Program Expands, Doubling In Size
      • Elotuzumab Receives Breakthrough Therapy Designation For Multiple Myeloma
      • Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2014)
      • Common Solvent Appears To Have Anti-Myeloma Activity
      • Researchers Review Current Diagnostic Imaging Techniques For Multiple Myeloma
    • ► April (5)
      • Siltuximab (Sylvant) Gains FDA Approval ... But Not For Multiple Myeloma
      • Beacon NewsFlashes - April 26, 2014
      • The Myeloma Quiz - April 2014
      • Minimal Residual Disease, Deep Sequencing, And Prognosis In Multiple Myeloma
      • Researchers Publish Results Of Revlimid-Velcade-Dexamethasone Trial In Relapsed Multiple Myeloma
    • ► March (8)
      • Large Study Sheds New Light On Tissue-Type Mismatches And Their Impact On Donor Stem Cell Transplant Outcomes
      • Levels Of Uninvolved Immunoglobulins Linked To Prognosis In Newly Diagnosed Multiple Myeloma
      • Researchers Express Concern About Scar Tissue And Extramedullary Disease In Multiple Myeloma Patients
      • Regular Whole-Body MRI Scans May Identify Smoldering Myeloma Patients At High Risk For Progression
      • Patterns Of Post-Transplant Relapse And Progression Vary Among Multiple Myeloma Patients
      • Revlimid And Secondary Cancers: Melphalan May Be The Culprit
      • Revlimid-Dexamethasone Has Mixed Effects On Bone Disease In Relapsed/Refractory Multiple Myeloma
      • The Top Myeloma Research Of 2013
    • ► February (8)
      • Degree Of Complete Response After Transplant May Affect Survival In Myeloma
      • DCEP May Serve As Bridging Therapy For Relapsed Multiple Myeloma
      • The Top Myeloma Beacon Patient Columns Of 2013
      • Multiple Myeloma Molecular Subtypes Are Already Present In MGUS And Smoldering Myeloma Patients
      • The Top Myeloma Beacon News Articles Of 2013
      • Pomalyst Approved In Canada For Relapsed And Refractory Multiple Myeloma
      • Pomalyst-Based Combination Regimens Presented At ASH 2013
      • Continuous Revlimid-Dexamethasone Therapy Delays Progression And Improves Survival In Older Newly Diagnosed Myeloma Patients (ASH 2013)
    • ► January (5)
      • Injection Site Reactions Less Frequent After First Cycle Of Subcutaneous Velcade
      • Broad Range Of Kyprolis Studies Presented At ASH 2013
      • Top 10 Discoveries Of 2013 In Multiple Myeloma
      • Researchers Take A Closer Look At Extended Revlimid-Dexamethasone Therapy For Newly Diagnosed Myeloma
      • Additional Analyses Of Pomalyst Plus Low-Dose Dexamethasone Studies Presented At ASH 2013
  • ►2013 (157)
    • ► December (11)
      • Further Evidence Of A Positive Link Between Weight At Diagnosis And Survival In Multiple Myeloma Patients
      • Filanesib (ARRY-520) Continues To Show Promise In Heavily Pretreated Multiple Myeloma Patients (ASH 2013)
      • SAR650984 Shows Encouraging Early Results For Heavily Pretreated Multiple Myeloma (ASH 2013)
      • ASH 2013 Multiple Myeloma Update - Day Three: Morning Oral Sessions
      • ASH 2013 Multiple Myeloma Update - Day Three: Afternoon Oral Sessions
      • ASH 2013 Multiple Myeloma Update - Day Three Overview
      • ASH 2013 Multiple Myeloma Update - Day Two
      • ASH 2013 Multiple Myeloma Update - Day One
      • ASH 2013 Multiple Myeloma Gateway Now Available
      • ASH 2013 Preview: Smoldering Myeloma And MGUS
      • ASH 2013 Preview: Revlimid Maintenance Therapy For Multiple Myeloma
    • ► November (9)
      • Extended Post-Transplant Treatment With Revlimid, Velcade, And Dexamethasone Yields High Survival Rates In High-Risk Myeloma
      • ASH 2013 Preview: Novel Immunotherapies Under Development For The Treatment Of Multiple Myeloma
      • ASH 2013 Preview: Treatments In Mid- To Late-Stage Clinical Development For Multiple Myeloma
      • ASH 2013 Preview: Treatments In Early-Phase Clinical Development For Multiple Myeloma
      • ASH 2013 Preview: The Newest Multiple Myeloma Treatments On The Horizon
      • Multiple Myeloma Abstracts From The 2013 American Society Of Hematology Meeting Are Now Available At The Myeloma Beacon (ASH 2013)
      • Chromosomal Abnormalities And Tumor Load Linked To More Rapid Progression In Smoldering Myeloma Patients
      • Dinaciclib Combination To Be Tested In Multiple Myeloma Clinical Trial
      • Survival Of Multiple Myeloma Patients Significantly Increases Over Last Decade
    • ► October (14)
      • Whole-Body MRI Helps Identify MGUS Patients At Risk For Progression To Symptomatic Disease
      • Stem Cell Transplantation Effective In Myeloma Patients With Advanced Kidney Disease, But Has Limited Impact On Kidney Function
      • Clinical Trial To Test Fenofibrate (Tricor) As Anti-Myeloma Therapy
      • "Chemo Brain" May Affect Half Of Myeloma Patients After Initial Therapy, And Is Worsened By Stem Cell Transplantation
      • Milatuzumab Alone Shows Limited Efficacy In Relapsed and Refractory Myeloma Patients
      • Respiratory Tract Infections And Shingles Linked To An Increased Risk Of Developing Multiple Myeloma
      • Chromosomal Abnormalities May Influence Myeloma Symptoms At Diagnosis
      • Addition Of Zolinza Slightly Improves Velcade Treatment For Relapsed Myeloma Patients
      • Beacon NewsFlashes – October 14, 2013
      • Immune Function Linked To Long-Term Survival In Multiple Myeloma
      • Velcade-Treanda-Prednisone Combo Demonstrates Efficacy And Improves Kidney Function In Relapsed And Refractory Myeloma Patients
      • Beacon NewsFlashes – October 7, 2013
      • Extended Use Of Revlimid Plus Dexamethasone Delays Progression Of Relapsed / Refractory Myeloma
      • Pomalyst-Cyclophosphamide-Prednisone Combination Effective And Safe In Relapsed Multiple Myeloma
    • ► September (11)
      • Multiple Myeloma And Pregnancy
      • Beacon NewsFlashes - September 25, 2013
      • Doxil With Revlimid And Dexamethasone Falls Short As Therapy For Newly Diagnosed Myeloma
      • Kyprolis-Revlimid-Dexamethasone Combination Continues To Show Promise For Relapsed Myeloma
      • Researchers Publish Final Results Of Pomalyst Trial That Led To Approval In Europe
      • Panobinostat-Velcade-Dexamethasone Combination Continues To Show Promise For Heavily Pretreated Myeloma
      • Experts Publish Consensus Risk Classification For Multiple Myeloma
      • Aspirin Not As Effective As Other Agents In Preventing Blood Clots During Myeloma Treatment With Thalidomide Or Revlimid
      • Beacon NewsFlashes – September 9, 2013
      • Study Finds Revlimid-Dexamethasone Is Effective And Safe For Relapsed / Refractory Myeloma In ‘The Real World’
      • Kyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?
    • ► August (16)
      • Multiple Myeloma Survival Increased Significantly The Past 15 Years, But Unevenly Across Ethnic And Age Groups
      • Researchers Recommend Newer Methods To Assess Kidney Disease In Newly Diagnosed Multiple Myeloma Patients
      • Beacon NewsFlashes - August 26, 2013
      • Amgen To Acquire Onyx, Maker Of Kyprolis; What Does It Mean For The Myeloma Community?
      • Continued Response After Stem Cell Transplantation For Myeloma May Signal Improved Survival
      • Protein Biomarkers May Predict Onset Of Acute GVHD After Donor Stem Cell Transplantation
      • Transplantation With Stem Cells Collected After An Initial Transplant May Increase A Myeloma Patient's Risk Of Developing MDS
      • Beacon NewsFlashes – August 19, 2013
      • Early Or Late Stem Cell Transplantation For Myeloma? New Study Finds Both Strategies Yield Similar Overall Survival
      • Italian Study Documents Efficacy And Safety Of Velcade Plus Dexamethasone In Relapsed Multiple Myeloma
      • Beacon NewsFlashes – August 12, 2013
      • Should Myeloma Patients Panic If They Do Not Achieve A Complete Response?
      • Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma
      • New Comorbidity Index May Help Determine Multiple Myeloma Risk Level
      • Beacon NewsFlashes – August 5, 2013
      • Revlimid Plus Dexamethasone Delays Progression And Extends Survival In High-Risk Smoldering Myeloma
    • ► July (13)
      • Velcade, Doxorubicin, And Intermediate-Dose Dexamethasone May Be Effective In Relapsed / Refractory Myeloma Patients
      • Beacon NewsFlashes – July 29, 2013
      • Researchers Investigate Genetic Changes That Drive The Progression Of Myeloma
      • Researchers Assess Frequency And Prognostic Value Of Chromosomal Abnormalities In Older Myeloma Patients
      • Beacon NewsFlashes – July 22, 2013
      • Revlimid Leukemia Trial Halted – No Immediate Impact On Drug's Use In Myeloma Expected
      • Velcade Before And After Donor Stem Cell Trans­plan­tation May Improve The Efficacy And Safety For High-Risk Myeloma Patients
      • Beacon NewsFlashes – July 15, 2013
      • Older Myeloma Patients Treated With Novel Agents May Be At Increased Risk For Engraftment Syndrome After Transplantation
      • Sequential Treatment With Novel Agents Is Effective And Safe In Older, Newly Diagnosed Myeloma Patients
      • Researchers Develop Model To Identify Myeloma Patients With MGUS-Like Disease
      • Beacon NewsFlashes - July 3, 2013
      • Beacon NewsFlashes – July 1, 2013
    • ► June (15)
      • Researchers Propose "Blueprint" For Pursuing A Multiple Myeloma Cure
      • Experts Publish Treatment Recommendations For Multiple Myeloma-Related Bone Disease
      • Beacon NewsFlashes – June 24, 2013
      • Two New Studies Investigate The Significance Of Minimal Residual Disease In Multiple Myeloma
      • Study Sheds Light On Impact Of Chromosomal Abnormality t(11;14) On Post-Transplant Outcomes Among Myeloma Patients
      • Beacon NewsFlashes – June 17, 2013
      • A Look At The Myeloma-Related Poster Presentations At The EHA Congress (EHA 2013)
      • The European Hematology Association’s Annual Congress Starts Today: A Look At The Key Myeloma-Related Presentations (EHA 2013)
      • ASCO 2013 And Multiple Myeloma: What Were The Highlights?
      • Cell-Based Myeloma Vaccine May Deepen Responses After Stem Cell Transplantation
      • ASCO 2013 Multiple Myeloma Update – Day Four: Poster Presentations
      • ASCO 2013 Multiple Myeloma Update – Day Four: Oral Presentations
      • ASCO 2013 Multiple Myeloma Update – Day Three: Poster Presentations
      • ASCO 2013 Multiple Myeloma Update – Day Two: Education Session
      • Pomalidomide Gets Positive Opinion From European Advisory Committee; Approval Expected By End Of Summer
    • ► May (11)
      • Beacon NewsFlashes - May 31, 2013
      • New Study Further Documents Trends In Stem Cell Transplantation For Multiple Myeloma
      • The Future Of Treatment For Multiple Myeloma
      • Kyprolis Shows Good Response Rates In Heavily Pretreated High-Risk Myeloma Patients
      • Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2013)
      • Novel Agents Followed By Repeat Transplantation May Be Effective For Relapsed Myeloma
      • Velcade Consolidation Therapy After Stem Cell Transplantation May Improve Outcomes Of Myeloma Patients
      • Beacon NewsFlashes – May 13, 2013
      • Donor Stem Cell Transplant As Consolidation Therapy May Be Effective And Safe In Myeloma
      • Beacon NewsFlashes - May 6, 2013
      • Study Questions Conventional Wisdom On Revlimid And Stem Cell Collection
    • ► April (15)
      • Trends In The Treatment Of Newly Diagnosed Multiple Myeloma Patients
      • Beacon NewsFlashes – April 29, 2013
      • Spanish Expert Recommends Early Treatment For High-Risk Smoldering Myeloma (IMW 2013)
      • Beyond Kyprolis And Pomalyst: What Is Next On The Horizon?
      • Beacon NewsFlashes – April 22, 2013
      • Update On Benefits And Risks Of Revlimid Maintenance Therapy (IMW 2013)
      • Kyprolis-Revlimid-Dexamethasone Combo Shows Encouraging Results In Older Newly Diagnosed Myeloma Patients (IMW 2013)
      • Beacon NewsFlashes – April 15, 2013
      • Update Presented About Cereblon And Resistance To Pomalyst, Revlimid, And Thalidomide In Myeloma Patients (IMW 2013)
      • Pomalyst Plus Low-Dose Dexamethasone Is Active In High-Risk Relapsed Myeloma Patients (IMW 2013)
      • Kyprolis-Revlimid-Dexamethasone Combination Shows Promise In High-Risk Smoldering Myeloma (IMW 2013)
      • Beacon NewsFlashes – April 8, 2013
      • Additional Study Finds Auto-Allo Transplants Can Provide Long-Term Control Of Myeloma
      • The 14th International Myeloma Workshop Kicks Off Today (IMW 2013)
      • Beacon NewsFlashes – April 1, 2013
    • ► March (14)
      • Chromosomal Abnormalities May Identify Smoldering Myeloma Patients At Higher Risk of Progression
      • Long-Term Analysis Highlights Potential Survival Benefit Of Auto-Allo Transplantation In Multiple Myeloma
      • Beacon NewsFlashes - March 25, 2013
      • The Top Myeloma Research Of 2012
      • Advanced Age And Organ Damage Associated With Poor Survival In Elderly Myeloma Patients
      • Kyprolis-Revlimid-Dexamethasone Combination Added To NCCN Guidelines As Upfront Therapy For Myeloma
      • Mozobil Associated With An Increased Risk Of Secondary Cancer
      • Extramedullary Disease Presents Unique Symptoms And Challenges In Multiple Myeloma Patients
      • African-American Myeloma Patients May Have Fewer Chromosome 14 Translocations Than European-American Patients
      • Phase 3 Trial Of Perifosine In Myeloma Is Halted
      • Beacon NewsFlashes – March 11, 2013
      • Kyprolis-Revlimid-Dexamethasone Combination Is Effective For Relapsed Myeloma
      • Beacon NewsFlashes – March 6, 2013
      • Disease Status May Be Key To Outcome Of Second Stem Cell Transplant In Multiple Myeloma Patients
    • ► February (14)
      • French Study Provides Further Insights Into Pomalyst's Efficacy, Safety, And Dosing
      • Velcade-Dexamethasone Plus Donor Lymphocyte Infusions In Myeloma Patients Relapsing After Donor Stem Cell Transplantation
      • Beacon NewsFlashes – February 25, 2013
      • Pomalyst – Which Multiple Myeloma Patients Will Physicians Treat With It?
      • Velcade-Based Therapy May Improve Outcomes For Myeloma Patients Who Do Not Respond Well To Initial Therapy With Revlimid Or Thalidomide
      • Kyprolis In Multiple Myeloma Patients With Kidney Damage
      • Pomalyst - Questions And Answers About The FDA Approval
      • Beacon NewsFlashes – February 11, 2013
      • Spanish Translations Of Select Articles Now Available At The Myeloma Beacon
      • Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma
      • Pomalidomide (Pomalyst) - The Waiting Game
      • Tandem Auto-Allo Transplantation May Improve Prognosis Of High-Risk Myeloma Patients
      • Beacon NewsFlashes – February 4, 2013
      • Long-Term Revlimid-Clarithromycin-Dexamethasone Is Effective And Safe In Newly Diagnosed Myeloma Patients
    • ► January (14)
      • Short-Term Velcade-Based Combination Therapies May Be Effective And Safe For Multiple Myeloma
      • Novel Myeloma Therapies May Not Hinder Stem Cell Collection
      • Beacon NewsFlashes – January 28, 2013
      • The Top Myeloma Beacon Patient And Caregiver Columns Of 2012
      • Mayo, PETHEMA, And The Risk Of Progression In Smoldering Myeloma: More Disagreement Than Agreement
      • Trends In The Use Of Stem Cell Transplantation For Multiple Myeloma (ASH 2012)
      • Beacon NewsFlashes – January 21, 2013
      • The Top Myeloma Beacon News Articles Of 2012
      • Different M-Spike After Stem Cell Transplantation Linked To Improved Survival (ASH 2012)
      • Beacon NewsFlashes – January 14, 2013
      • Risk Of Infection Among Multiple Myeloma Patients Is High And Rising (ASH 2012)
      • Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)
      • ‘Pomalyst’ Is Proposed Brand Name For Pomalidomide
      • Lorvotuzumab Mertansine Combination Effective In Relapsed/Refractory Multiple Myeloma Patients (ASH 2012)
  • ►2012 (181)
    • ► December (20)
      • Tabalumab Plus Velcade Shows Therapeutic Benefit In Previously Treated Multiple Myeloma Patients (ASH 2012)
      • Multiple Myeloma And The ASH 2012 Meeting: Taking Stock And Tagging The Highlights
      • Beacon NewsFlashes – December 19, 2012
      • Dinaciclib Shows Activity In Relapsed Multiple Myeloma (ASH 2012)
      • Circularly Permuted TRAIL May Be Effective For Relapsed/Refractory Multiple Myeloma (ASH 2012)
      • ARRY-520 Shows Encouraging Early Results For Relapsed And Refractory Myeloma (ASH 2012)
      • ASH 2012 Multiple Myeloma Update – Day Four: Oral Session
      • ASH 2012 Multiple Myeloma Update – Day Three: Poster Sessions
      • ASH 2012 Multiple Myeloma Update – Day Three: Late Afternoon Oral Session
      • ASH 2012 Multiple Myeloma Update – Day Three: Early Afternoon Oral Session
      • ASH 2012 Multiple Myeloma Update – Day Three: Late Morning Oral Session
      • ASH 2012 Multiple Myeloma Update – Day Three: Early Morning Oral Session
      • ASH 2012 Multiple Myeloma Update – Day Two: Poster Sessions
      • ASH 2012 Multiple Myeloma Update – Day Two: Late Afternoon Oral Session
      • ASH 2012 Multiple Myeloma Update – Day Two: Early Afternoon Oral Session
      • ASH 2012 Multiple Myeloma Update – Day One: Poster Sessions
      • Tips For Making Sense Of The Research Results Presented At This Year’s ASH Annual Meeting
      • Stem Cell Transplants Linked To Higher Risk Of Irregular Heart Beat In Multiple Myeloma Patients
      • Beacon NewsFlashes – December 5, 2012
      • Myeloma Patients With Early Relapse After Stem Cell Transplant May Benefit From Second Transplant With Melphalan-Velcade
    • ► November (11)
      • The Myeloma Beacon To Report The Latest Research From The Upcoming American Society Of Hematology Annual Meeting (ASH 2012)
      • Personal Perspective: Smoldering Myeloma Patient Becomes Her Own Best Advocate
      • Second Transplant May Be An Effective And Safe Salvage Therapy For Certain Relapsed/Refractory Myeloma Patients
      • Beacon NewsFlashes – November 26, 2012
      • Beacon NewsFlashes – November 21, 2012
      • New Multiple Myeloma Treatments On The Horizon (ASH 2012)
      • Study Identifies Factors Linked To Longer Survival Among Myeloma Patients Receiving Stem Cell Transplants
      • Lower-Dose Velcade-Melphalan-Prednisone Regimen May Be An Effective And Safe Salvage Therapy For Older Multiple Myeloma Patients
      • Kidney Transplants: Should More Multiple Myeloma Patients Receive Them?
      • Heavy/Light Chain Test May Be Valuable Tool For Monitoring Multiple Myeloma
      • Intravenous Busulfan-Melphalan Combo May Be As Effective As Melphalan Prior To Stem Cell Transplant In Multiple Myeloma
    • ► October (14)
      • Beacon NewsFlashes - October 29, 2012
      • Researchers Develop Vulnerability Score To Better Assess Survival In Multiple Myeloma Patients
      • Pomalidomide Shows Survival Benefit In Heavily Pretreated Myeloma Patients
      • Beacon NewsFlashes – October 22, 2012
      • Donor Stem Cell Transplants In Multiple Myeloma May Be More Beneficial Upfront Than At Relapse
      • Velcade and Thalidomide May Increase Risk For Abnormal Lung Function In Multiple Myeloma Patients
      • Stem Cell Transplants May Increase Risk Of Heart Disease
      • Beacon NewsFlashes – October 15, 2012
      • Study Favors PET-CT Scans Over Whole-Body MRI In Determining Response To Myeloma Treatment
      • Thalidomide May Delay Disease Progression In Patients With Smoldering Myeloma
      • Velcade-Cyclophosphamide-Dexamethasone Combination May Be Effective In Myeloma Patients With Kidney Damage
      • Pomalidomide FDA Advisory Committee Meeting Canceled
      • Smoldering Myeloma Patients With High Percentage Of Plasma Cells In The Blood Are At Increased Risk Of Early Progression
      • Beacon NewsFlashes – October 1, 2012
    • ► September (11)
      • Kepivance May Increase The Tolerability Of Higher Doses Of Melphalan For Multiple Myeloma
      • New Agents In Combination With Revlimid Show Promise For Relapsed / Refractory Multiple Myeloma
      • Personal Perspective: Former Nurse Battles MGUS And Other Immune Disorders With A Positive Attitude
      • Beacon NewsFlashes – September 24, 2012
      • Revlimid-Velcade-Dexamethasone May Be An Option For Advanced Multiple Myeloma
      • FDA Sets Date For Pomalidomide Advisory Committee Meeting
      • Beacon NewsFlashes – September 17, 2012
      • Blood Tests May Be Sufficient To Monitor For Relapse Or Progression Of Multiple Myeloma After Stem Cell Transplantation
      • Study Compares MRI And PET-CT Scans For Evaluation Of Multiple Myeloma
      • Study Confirms Higher Progression Risk For Smoldering Myeloma Patients With High Percentage Of Plasma Cells In Bone Marrow
      • Initial Treatment With Velcade-Thalidomide-Dexamethasone Combo Improves Responses Before And After Stem Cell Transplantation
    • ► August (15)
      • Gene Therapy To Treat Leukemia And Multiple Myeloma: An Update
      • Research Sheds Light On The Immune System Of Multiple Myeloma Patients With Long-Term Disease Control
      • Velcade-Thalidomide And Velcade-Prednisone May Be Effective As Maintenance Therapy For Elderly Myeloma Patients
      • Oligosecretory Myeloma Can Often Be Detected With Free Light Chain Assay
      • Beacon NewsFlashes – August 23, 2012
      • Revlimid Maintenance Therapy Gets NCCN Vote Of Confidence
      • Donor Stem Cell Transplantation Plus Revlimid Maintenance May Be Effective For Relapsed / Refractory Multiple Myeloma
      • Kyprolis - Which Multiple Myeloma Patients Will Physicians Treat With It?
      • Beacon NewsFlashes – August 15, 2012
      • Xgeva Is Better Than Zometa In Reducing Pain Associated With Bone Disease
      • Study Confirms Survival Benefit Of Revlimid-Dexamethasone Combo In Elderly Relapsed / Refractory Myeloma Patients
      • Novel Agents Help Reverse Kidney Impairment In Newly Diagnosed Multiple Myeloma Patients
      • Researchers Publish Final Results Of Kyprolis Study That Led To FDA Approval
      • Number of Bone Lesions After Stem Cell Transplant May Predict Overall Survival
      • Beacon NewsFlashes – August 1, 2012
    • ► July (14)
      • Better Treatments For Extramedullary Myeloma Still Needed
      • Maintenance Therapy For Multiple Myeloma (ASCO 2012)
      • Beacon NewsFlashes – July 26, 2012
      • Kyprolis - Questions And Answers About The FDA Approval
      • Velcade-Thalidomide-Dexamethasone Superior To Thalidomide-Dexamethasone In Myeloma Patients Relapsing After Transplant
      • FDA Approves Kyprolis (Carfilzomib) For Relapsed And Refractory Multiple Myeloma
      • Preventative Antibiotics May Not Decrease Infections In Myeloma Patients Undergoing Initial Treatment
      • Cyclophosphamide-Thalidomide-Dexamethasone May Deepen Responses After Stem Cell Transplantation
      • To Maintain Or Not To Maintain – That Is The Question!
      • Beacon NewsFlashes – July 11, 2012
      • Revlimid-Treanda-Prednisone Combo Is Active And Well Tolerated For Relapsed/Refractory Myeloma (EHA 2012)
      • The Role Of Stem Cell Transplantation In Multiple Myeloma (ASCO 2012)
      • Beacon NewsFlashes – July 4, 2012
      • Research Provides Insight Into Genetic Changes Responsible For Multiple Myeloma (EHA 2012)
    • ► June (26)
      • Individualized Therapy For Newly Diagnosed Multiple Myeloma (ASCO 2012)
      • Quality Of Response Following Stem Cell Transplant May Predict Long-Term Survival In Myeloma Patients (EHA 2012)
      • Beacon NewsFlashes – June 26, 2012
      • Updated Pomalidomide Clinical Trial Results Presented (ASCO 2012)
      • Safety Concerns Force Withdrawal Of Revlimid Application For Expanded Use In Europe
      • Pomalidomide Gets Standard FDA Review And Application For European Approval
      • Carfilzomib Earns Strong Positive Vote From FDA Advisory Committee
      • Live Coverage Of The Carfilzomib FDA Advisory Committee Meeting
      • FDA "Very Concerned" About Carfilzomib's Safety
      • FDA Releases Key Documents Related To Carfilzomib Advisory Committee Meeting
      • Carfilzomib To Face Critical FDA Advisory Committee Meeting Next Week
      • MLN9708 Shows Encouraging Results For The Treatment Of Multiple Myeloma (ASCO 2012)
      • Myeloma Research To Be Presented At The European Hematology Association's Annual Congress (EHA 2012)
      • Elotuzumab Combination Continues To Show Promise As Treatment For Multiple Myeloma (ASCO 2012)
      • Beacon NewsFlashes – June 12, 2012
      • Extensive Carfilzomib Clinical Trial Results Presented (ASCO 2012)
      • Daratumumab Shows Promise As Treatment For Relapsed / Refractory Multiple Myeloma (ASCO 2012)
      • ASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On Various Myeloma-Related Topics
      • ASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On Current Myeloma Treatments
      • ASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On New Myeloma Treatments
      • ASCO 2012 Multiple Myeloma Update – Day Four: Immunotherapy For Myeloma
      • ASCO 2012 Multiple Myeloma Update – Day Three: New Myeloma Treatments
      • ASCO 2012 Multiple Myeloma Update – Day Three: Carfilzomib And Pomalidomide
      • ASCO 2012 Multiple Myeloma Update – Day Two: Education Session
      • ASCO 2012 Multiple Myeloma Update – Day Two: Poster Session
      • Velcade-Treanda-Prednisone Combination May Be Effective In Newly Diagnosed Myeloma Patients With Kidney Impairment
    • ► May (14)
      • Beacon NewsFlashes - May 30, 2012
      • Day Of Rest Between Melphalan And Stem Cell Infusion May Not Be Necessary For Myeloma Patients
      • Detection Of Bone Lesions In Multiple Myeloma Patients Is Better With CT Scans
      • New Multiple Myeloma Treatments On The Horizon (ASCO 2012)
      • Researchers Identify Factors That Predict Long-Term Survival In Newly Diagnosed Myeloma Patients
      • Re-Infused Lymphocyte Dose May Not Influence Outcomes After Upfront Stem Cell Transplantation
      • Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 48th Annual Meeting (ASCO 2012)
      • Beacon NewsFlashes – May 14, 2012
      • Revlimid Maintenance Therapy: Three Major Studies Clarify The Benefits And Risks
      • New Study Highlights Role Of Blood Clots In Multiple Myeloma Survival
      • FDA Issues Extensive Update About Revlimid And Second Cancers
      • Development Of Perifosine For Multiple Myeloma To Continue
      • Solitary Bone Plasmacytoma – What Every Patient Should Know
      • Beacon NewsFlashes – May 2, 2012
    • ► April (15)
      • Gain In Chromosome 1 Negatively Affects Prognosis Only In Certain Newly Diagnosed Myeloma Patients
      • ‘Kyprolis’ Is Proposed Brand Name For Carfilzomib
      • FDA Sets Date For Carfilzomib Advisory Committee Meeting
      • Celgene Submits Pomalidomide For FDA Approval
      • Addition Of Velcade Improves Thalidomide-Dexamethasone Consolidation Therapy For Newly Diagnosed Myeloma Patients
      • Beacon NewsFlashes – April 23, 2012
      • Mozobil May Help Revlimid-Treated Myeloma Patients Collect Enough Stem Cells For Transplantation
      • Upfront Treatment With Novel Agents Improves Survival In Elderly Myeloma Patients
      • Beacon NewsFlashes - April 16, 2012
      • Velcade-Melphalan And Double Stem Cell Transplant Combination Is Feasible In Treatment-Resistant Myeloma Patients
      • Heavy/Light Chain Ratios May Be A Prognostic Marker For Myeloma Patients
      • Two Myeloma Experts Debate Role Of Stem Cell Transplantation In The Treatment Of Multiple Myeloma
      • Study Investigates Cement Leakage Risk Following Vertebroplasty And Kyphoplasty In Myeloma Patients
      • Beacon NewsFlashes – April 4, 2012
      • Drug-Induced Peripheral Neuropathy In Multiple Myeloma Patients – Part 3: Prevention And Future Directions
    • ► March (15)
      • Drug-Induced Peripheral Neuropathy In Multiple Myeloma Patients – Part 2: Treatment
      • Beacon NewsFlashes - March 29, 2012
      • “Mini” Unrelated Donor Stem Cell Transplantation May Be Feasible In Multiple Myeloma Patients
      • Drug-Induced Peripheral Neuropathy In Multiple Myeloma Patients – Part 1: What Is It And Who Is At Risk?
      • Among Velcade-Based Combinations, Four-Drug Combo Is Not More Effective Than Similar Three-Drug Combos For Newly Diagnosed Multiple Myeloma
      • Study Supports Efficacy Of Revlimid-Dexamethasone Combination In Elderly Multiple Myeloma Patients With Relapsed Disease
      • Family History Of Blood Clots Increases Risk Of Clots In Myeloma Patients
      • Beacon NewsFlashes – March 19, 2012
      • Alternating Revlimid And Thalidomide Is As Effective As Either Drug Alone In Newly Diagnosed Multiple Myeloma Patients
      • Revlimid Prescribing Information Updated To Include Secondary Cancer Warning
      • Revlimid-Velcade-Doxil-Dexamethasone Combination May Be Effective And Tolerable In Relapsed/Refractory Myeloma
      • The Top Myeloma Research Of 2011
      • Curcumin May Reduce Free Light Chains In Patients With MGUS And Smoldering Multiple Myeloma
      • Velcade Followed By Thalidomide As Maintenance Therapy Yields Positive Initial Results
      • Understanding Prognosis In Multiple Myeloma
    • ► February (13)
      • Revlimid May Boost Vaccine Responses In Multiple Myeloma Patients
      • High Cut-Off Hemodialysis Helps Restore Kidney Function In Multiple Myeloma Patients
      • Velcade-Based Therapy May Improve Survival Of Multiple Myeloma Patients With Deletion In Chromosome 17
      • Onyx: No Real News To Report About Carfilzomib And The FDA
      • Myeloma Precursor Disease MGUS May Increase Risk Of Developing Infections
      • Beacon NewsFlashes – February 20, 2012
      • Study Finds Donor Lymphocyte Infusions Are More Effective When Used Preemptively In Myeloma Transplant Patients
      • High-Risk Myeloma Patients With Trisomies May Not Be High Risk After All
      • Sequence Of Velcade And Revlimid Treatment May Not Matter In Many Multiple Myeloma Patients (ASH 2011)
      • Perifosine Combination May Be Effective In Relapsed/Refractory Multiple Myeloma (ASH 2011)
      • Beacon NewsFlashes – February 6, 2012
      • Siltuximab May Be Effective In Certain Patients With Advanced Multiple Myeloma (ASH 2011)
      • Experts Publish Consensus Statement On Maintenance Therapy In Multiple Myeloma
    • ► January (13)
      • The Top Myeloma Beacon Patient And Caregiver Columns Of 2011
      • Celgene Updates Timeline For Pomalidomide Approval In The U.S. And Europe
      • Questions And Answers About The FDA’s Approval Of Subcutaneous Velcade
      • Beacon BreakingNews – Subcutaneous Velcade Receives FDA Approval
      • Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011)
      • The Top Myeloma Beacon Resource Articles Of 2011
      • BT-062 Shows Activity In Patients With Advanced Myeloma (ASH 2011)
      • Panobinostat Combination May Be Effective In Relapsed And Velcade-Refractory Multiple Myeloma (ASH 2011)
      • Smoldering Myeloma: What Do The Latest Research Findings Mean? A Discussion With Dr. Ola Landgren
      • Beacon NewsFlashes - January 12, 2012
      • Revlimid-Dexamethasone Combination Delays Disease Progression In Patients With Smoldering Multiple Myeloma (ASH 2011)
      • The Top Myeloma Beacon News Articles Of 2011
      • Zolinza Tallies Mixed Results In Relapsed And Refractory Multiple Myeloma Patients (ASH 2011)
  • ►2011 (176)
    • ► December (17)
      • Pomalidomide Continues To Show Promise As Treatment For Relapsed Multiple Myeloma (ASH 2011)
      • ASH 2011 – The Meeting’s Myeloma-Related “Hidden Gem”
      • ASH 2011 – Initial Thoughts On The Meeting's Key Myeloma-Related Findings
      • ASH 2011 Multiple Myeloma Update – Day Four
      • ASH 2011 Multiple Myeloma Update – Day Three Afternoon: Other New Therapies
      • ASH 2011 Multiple Myeloma Update – Day Three Afternoon: Carfilzomib And Pomalidomide
      • MLN9708, "Son of Velcade," Shows Promising Initial Results In Multiple Myeloma (ASH 2011)
      • Elotuzumab Combination Effective For Relapsed And Refractory Multiple Myeloma (ASH 2011)
      • ASH 2011 Multiple Myeloma Update – Day Three Morning: Current Therapies
      • ASH 2011 Multiple Myeloma Update – Day Three Morning: New Therapies
      • ASH 2011 Multiple Myeloma Update – Day Two
      • Beacon Breaking News - Carfilzomib To Get Standard, Not Priority, FDA Review
      • ASH 2011 Multiple Myeloma Update – Day One
      • Spanish Experts Ask: What Is The Path To A Cure For Myeloma?
      • The Myeloma Beacon To Provide Comprehensive Coverage Of The 2011 American Society Of Hematology Meeting (ASH 2011)
      • Initial Treatment With Cyclophosphamide, Velcade, And Dexamethasone Compares Favorably In Terms Of Response Rates And Side Effects
      • Czech Researchers Look At Impact Of Chromosomal Abnormalities In Newly Diagnosed Multiple Myeloma
    • ► November (11)
      • Beacon NewsFlashes - November 30, 2011
      • Beacon Breaking News - FDA Accepts Carfilzomib New Drug Application
      • Genetic Differences Linked To Increased Risk Of Multiple Myeloma
      • Canadian Study Takes In-Depth Look At Second Stem Cell Transplants As Salvage Therapy
      • High Sclerostin Levels Linked To Advanced Disease And Poor Bone Formation In Multiple Myeloma Patients
      • Disease Stability Affects Transplant Outcomes In Myeloma Patients Unresponsive To Initial Treatment
      • Lower-Dose Thalidomide Compares Well To Higher-Dose Option In Treatment Of Advanced Myeloma Patients
      • New Review Looks At Treatment Strategies For Relapsed And Refractory Multiple Myeloma Patients – Part 2: Treatment Strategies At Relapse
      • New Review Looks At Treatment Strategies For Relapsed And Refractory Multiple Myeloma – Part 1: Retreatment With Novel Agents
      • Extramedullary Myeloma
      • Thalidomide Maintenance Therapy Fails To Provide Consistent Overall Survival Benefit
    • ► October (11)
      • Study Finds Early And Delayed Stem Cell Transplants Have Comparable Efficacy In Newly Diagnosed Multiple Myeloma Patients
      • Thalidomide-Based Therapy Yields Mixed Outcomes In Multiple Myeloma Patients With A Deletion In Chromosome 17
      • Beacon NewsFlashes - October 26, 2011
      • Experts Review Current And Future Research Into New Multiple Myeloma Treatments
      • Myeloma Patients Relapsing After Pomalidomide Therapy May Benefit From Certain Salvage Therapies
      • Treanda In Combination With Steroids May Be Effective In Relapsed And Refractory Multiple Myeloma Patients
      • Neupogen And Neulasta Show Comparable Activity In Multiple Myeloma Patients After Stem Cell Transplantation
      • Myeloma Beacon Introduces New Service For Tracking Postings At Myeloma-Related Blogs
      • NCCN Modifies Guidelines For Multiple Myeloma A Second Time In 2011
      • Addition Of Doxil To Velcade Improves Treatment Outcomes For Multiple Myeloma Patients
      • Istodax-Velcade-Dexamethasone Combination May Be Effective In Relapsed/Refractory Myeloma
    • ► September (16)
      • Laser Surgery May Be An Effective Alternative For The Treatment Of Jawbone Death
      • High Level Of Stem Cells In The Blood May Be Associated With Favorable Prognosis For Myeloma Patients
      • Beacon BreakingNews - Onyx Submits Carfilzomib For FDA Approval
      • Beacon NewsFlashes – September 26, 2011
      • Recent Advances In The Treatment Of Myeloma Bone Disease
      • European Regulators Conclude Revlimid Safety Review, Say Drug's Benefit-Risk Balance Remains Positive
      • Results Of PET/CT Scans May Predict Survival In Multiple Myeloma Patients
      • Researchers Find High Rates Of Sexual Dysfunction After Stem Cell Transplantation
      • Multiple Myeloma Experts Recommend Tailored Therapies For Elderly Myeloma Patients
      • Sequential Treatment Using Velcade And Thalidomide Is Effective In High-Risk Multiple Myeloma Patients
      • Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 4: Novel Agent Use In Specific Patient Populations
      • Stem Cell Transplantation As Salvage Therapy Is Most Effective In Myeloma Patients With Previous Long Remission
      • Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 3: Revlimid-Related Side Effects
      • Myeloma Beacon Launches Sponsorship Program And Patient Advisory Board
      • Beacon NewsFlashes – September 5, 2011
      • Subcutaneous Velcade: Information For Multiple Myeloma Patients
    • ► August (18)
      • Researchers Determine Outcomes For Myeloma Patients Who Have Failed To Respond To Novel Agent Therapies
      • Beacon NewsFlashes – August 30, 2011
      • Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 2: Thalidomide-Related Side Effects
      • “Mini” Donor Stem Cell Transplant As Second Transplant May Improve Outcomes In Myeloma
      • Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 1: Velcade-Related Side Effects
      • Beacon NewsFlashes – August 24, 2011
      • Study Suggests MGUS Patients Receive Inadequate Evaluation, Follow-Up, And Treatment
      • Revlimid Maintenance Therapy After Donor Stem Cell Transplantation Is Not Recommended For Multiple Myeloma Patients
      • Stem Cell Transplants May Be Feasible In Elderly Multiple Myeloma Patients
      • Beacon NewsFlashes - August 15, 2011
      • Treating Multiple Myeloma Patients: Optimizing Response While Minimizing Side Effects
      • Gene Therapy Advance In Leukemia Suggests New Treatment Options For Multiple Myeloma
      • Multiple Myeloma And MGUS Patients May Have An Increased Risk Of Developing Certain Cancers
      • Addition Of Cyclophosphamide To Revlimid And Dexamethasone May Improve Responses In Newly Diagnosed Myeloma Patients
      • Beacon NewsFlashes – August 8, 2011
      • The Role Of Autologous Stem Cell Transplantation In Multiple Myeloma
      • Residual Disease Before Stem Cell Transplantation May Predict Survival In Multiple Myeloma Patients
      • Beacon NewsFlashes – August 1, 2011
    • ► July (12)
      • Percentage Of Cancerous Plasma Cells Post Transplant May Predict Outcome In Myeloma Patients
      • Cyclophosphamide-Thalidomide-Dexamethasone Improves Response But Not Survival In Elderly Myeloma Patients
      • Beacon NewsFlashes – July 25, 2011
      • New Response Type May Help Determine Multiple Myeloma Patients’ Prognoses
      • Melphalan-Prednisone-Thalidomide Combination May Increase Survival In Elderly Multiple Myeloma Patients
      • Donor Stem Cell Transplantation May Benefit High-Risk Myeloma Patients
      • Fatigue And Multiple Myeloma: Study Highlights Role Of Mood, Reevaluates Role Of Pain
      • Velcade-Dexamethasone Maintenance Therapy Appears To Be Effective In Myeloma Patients Who Respond To Velcade Rescue Therapy
      • Obesity's Impact On Myeloma Stem Cell Transplant Outcomes: Not What You Probably Expected
      • Steroid-Free Three-Drug Combination Treatment May Be Effective In Multiple Myeloma
      • Beacon NewsFlashes - July 4, 2011
      • Stem Cell Collection Is Feasible After Short-Course Revlimid For Myeloma Patients
    • ► June (17)
      • Early Relapse May Be Linked To Shorter Survival In Elderly Myeloma Patients
      • Experts Provide Guidelines To Help Myeloma Patients Prevent Infections (IMW 2011)
      • Velcade-Thalidomide-Dexamethasone May Be A Highly Effective Consolidation Therapy For Myeloma (EHA 2011)
      • Beacon NewsFlashes – June 20, 2011
      • Residual Disease And Chromosomal Abnormalities May Predict Early Myeloma Relapse (EHA 2011)
      • Transplantation Versus Novel Agents For Myeloma: Study Supports Transplantation (EHA 2011)
      • Myeloma Research To Be Presented At The European Hematology Association's Annual Congress (EHA 2011)
      • Elotuzumab Combination Is Effective For Relapsed Myeloma (ASCO 2011)
      • Investigational Drug LY2127399 Shows Potential For Myeloma (ASCO 2011)
      • ASCO 2011 Multiple Myeloma Update – Day Four
      • ASCO 2011 Multiple Myeloma Update – Day Three, Part Two
      • Lorvotuzumab Mertansine Combination Shows Activity In Myeloma (ASCO 2011)
      • Myeloma Experts Present Additional Data On Revlimid And Secondary Cancers (ASCO 2011)
      • ASCO 2011 Multiple Myeloma Update - Day Three, Part One
      • ASCO 2011 Multiple Myeloma Update - Days One And Two
      • Study Suggests Longer Infusion Time Does Not Improve Safety Of Zometa For Myeloma Patients
      • Experts Draft Guidelines For The Prevention Of Blood Clots In Multiple Myeloma Patients (IMW 2011)
    • ► May (16)
      • Complete Response After Stem Cell Transplant For Myeloma Indicates Best Prognosis
      • Certain Chromosomal Abnormalities May Negatively Affect Prognosis In Relapsed And Refractory Myeloma Patients Receiving Revlimid-Dexamethasone Therapy
      • Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 47th Annual Meeting (ASCO 2011)
      • Experts Develop Guidelines For Treating Anemia In Multiple Myeloma Patients (IMW 2011)
      • The 2011 International Myeloma Workshop - Key Themes and Learnings
      • Beacon NewsFlashes – May 20, 2011
      • Velcade-Doxil-Dexamethasone-Thalidomide Combination May Be Effective In Relapsed/Refractory Myeloma
      • Beacon NewsFlashes – May 16, 2011
      • Experts Recommend Intravenous Bisphosphonates For Multiple Myeloma Bone Disease (IMW 2011)
      • IMW 2011 Multiple Myeloma Update – Day 4
      • IMW 2011 Multiple Myeloma Update – Day Three Part 2
      • IMW 2011 Multiple Myeloma Update – Day Three Part 1
      • Beacon BreakingNews – Updated Data On Revlimid Maintenance And Second Cancers Presented At IMW
      • IMW 2011 Multiple Myeloma Update – Day Two
      • IMW 2011 Multiple Myeloma Update – Day One
      • Beacon NewsFlashes – May 2, 2011
    • ► April (15)
      • Researchers Identify Factors That May Put Multiple Myeloma Patients At Higher Risk For Osteonecrosis Of The Jaw
      • Thalidomide Receives New Safety Warning In Europe And Korea
      • More Studies Are Needed On Medications To Prevent Blood Clots In Multiple Myeloma Patients
      • Beacon NewsFlashes – April 25, 2011
      • Studies Aim To Improve Transplantation Response Rates In Multiple Myeloma Patients
      • Myeloma Research To Be Presented At The 13th International Myeloma Workshop
      • Mitoxantrone And Melphalan Regimen Is Effective And Well Tolerated In Multiple Myeloma Patients
      • Promising New Drugs For Myeloma: Will The Future Come Soon Enough?
      • Questions & Answers About The FDA’s Investigation Into The Safety of Revlimid And Thalidomide
      • Vertebroplasty Relieves Pain For Multiple Myeloma Patients With Spinal Fractures
      • FDA Announces Investigation Into Revlimid, Thalidomide, And Secondary Cancers
      • Mozobil May Help Myeloma Patients Collect Enough Stem Cells For A Second Transplant
      • Researchers Identify Risk Factors For Infectious Complications In Myeloma Patients Treated With Thalidomide-Based Combination Therapies
      • Beacon NewsFlashes – April 4, 2011
      • Pomalidomide May Be Effective In Myeloma Patients Who Develop Extramedullary Disease
    • ► March (14)
      • Aredia Does Not Prevent Disease Progression In Smoldering Myeloma Patients
      • Revlimid And Secondary Cancers: An Update
      • Beacon NewsFlashes - March 28, 2011
      • Beacon BreakingNews - European Multiple Myeloma Researchers Issue Statement on Revlimid and Secondary Cancers
      • Genome Sequencing Reveals Clues About The Underlying Causes Of Multiple Myeloma
      • NCCN Modifies Guidelines For Multiple Myeloma
      • New Advances In Myeloma Vaccines – Part 5: Participating In A Clinical Trial For A Novel Multiple Myeloma Vaccine
      • The Top Myeloma Research Of 2010
      • Beacon NewsFlashes - March 14, 2011
      • New Advances In Myeloma Vaccines – Part 4: Ongoing Research
      • Revlimid May Be Equally Effective In Thalidomide-Resistant and Thalidomide-Sensitive Multiple Myeloma Patients
      • Kyphoplasty Is More Effective Than Non-Surgical Care In Multiple Myeloma Patients With Spinal Fractures
      • New Advances In Myeloma Vaccines – Part 3: Completed Clinical Trials
      • Revlimid Dosing Will Continue In MM-015 Trial
    • ► February (14)
      • Thought Leader Perspective: Dr. Kenneth Anderson On The Future Of Myeloma Treatment
      • First Day Of Stem Cell Collection For Myeloma Patients Predicts Likelihood Of Collecting Enough Stem Cells For Transplantation
      • New Advances In Myeloma Vaccines – Part 2: Types Of Potential Myeloma Therapeutic Vaccines
      • Thought Leader Perspective: Dr. Kenneth Anderson On Treating Multiple Myeloma
      • New Advances In Myeloma Vaccines – Part 1: Introduction
      • Variations In Nervous System Genes May Put Multiple Myeloma Patients At Higher Risk For Thalidomide-Related Neuropathy
      • Myeloma Working Group Postpones Statement On Revlimid’s Potential Link To Second Cancers
      • Beacon NewsFlashes – February 14, 2011
      • Prognosis For Multiple Myeloma Patients With Chromosomal Abnormality t(4;14) Remains Poor
      • Split May Be Emerging Regarding Long-Term Revlimid Use
      • Beacon NewsFlashes - February 7, 2011
      • Revlimid Dosing To Continue In CALGB Maintenance Trial
      • Revlimid Cancer Controversy Flares
      • Bone Marrow Examination Can Predict Progression Of Multiple Myeloma
    • ► January (15)
      • Revlimid Maintenance And Secondary Cancers In Myeloma Patients: More Details Emerge
      • Thalidomide-Velcade Combination Without Steroids Is Effective For Newly Diagnosed Multiple Myeloma Patients
      • Chemotherapy Regimen Without High-Dose Dexamethasone Reduces Infections In Multiple Myeloma Patients
      • Beacon NewsFlashes – January 24, 2011
      • Novel Agents As Salvage Therapy After Stem Cell Transplantation Improve Survival In Multiple Myeloma Patients
      • Continued Revlimid-Dexamethasone Treatment May Improve Survival In Myeloma Patients Achieving A Partial Response
      • Targeted Irradiation And Stem Cell Transplantation Show Promise In Phase 1 Clinical Trial For Multiple Myeloma
      • The Majority Of Rare Myelomas Are Associated With Poorer Survival Than Common Myelomas
      • Beacon NewsFlashes – January 11, 2011
      • Revlimid And Pomalidomide Elicit High Response Rates In Multiple Myeloma Patients Who Relapsed After Thalidomide Or Revlimid (ASH 2010)
      • Torisel And Velcade Combination Shows Promise As Treatment For Relapsed/Refractory Multiple Myeloma (ASH 2010)
      • Beacon NewsFlashes - January 6, 2011
      • Experimental Drug PD 0332991 Shows Encouraging Phase 1 Trial Results In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010)
      • Treanda Shows Promising Activity In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010 Meeting)
      • Zolinza Shows Promise In Clinical Trials For The Treatment of Multiple Myeloma (ASH 2010)
  • ►2010 (200)
    • ► December (20)
      • Weekly Velcade Maintenance Therapy After Velcade-Based Initial Therapy Improves Response Rates In Elderly, Newly Diagnosed Myeloma Patients (ASH 2010)
      • Carfilzomib Shows Promise In Both Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients (ASH 2010)
      • Early Stem Cell Transplantation May Improve Survival In Newly Diagnosed Multiple Myeloma Patients (ASH 2010)
      • Elotuzumab Combinations Show Encouraging Results In Relapsed/Refractory Multiple Myeloma (ASH 2010)
      • Velcade Subcutaneous Injections Show Similar Activity But Fewer Side Effects Compared To IV Injections In Myeloma Patients (ASH 2010)
      • Beacon NewsFlashes – December 10, 2010
      • Studies Support Revlimid Maintenance Therapy For Multiple Myeloma Patients (ASH 2010)
      • ASH 2010 Multiple Myeloma Update – Day Four
      • ASH 2010 Multiple Myeloma Update – Day Three Afternoon And Evening
      • Zometa May Improve Survival In Myeloma Patients (ASH 2010)
      • ASH 2010 Multiple Myeloma Update – Day Three Morning
      • Pomalidomide Shows Promising Results For Multiple Myeloma Patients Resistant To Revlimid And Velcade (ASH 2010)
      • Donor Stem Cell Transplant Offers No Comparative Benefit As Second Transplant In Multiple Myeloma Patients (ASH 2010)
      • ASH 2010 Multiple Myeloma Update - Day Two
      • Carfilzomib Continues To Show Promising Results For Multiple Myeloma (ASH 2010)
      • ASH 2010 Multiple Myeloma Update – Day One
      • Risk-Adapted Therapy For Multiple Myeloma
      • The Myeloma Beacon To Provide Comprehensive Coverage Of The 2010 American Society Of Hematology Meeting
      • Latest Myeloma Research To Be Presented At The 52nd Meeting Of The American Society of Hematology (ASH 2010)
      • Beacon SiteUpdate – Physician Columns To Be Added To The Myeloma Beacon
    • ► November (16)
      • GlaxoSmithKline Halts All Further Development Of Resveratrol Drug SRT501
      • Certain Chromosomal Abnormalities Negatively Impact The Outcome Of Revlimid-Dexamethasone Therapy In Relapsed And Refractory Multiple Myeloma Patients
      • Turkish Translations Of Myeloma Beacon Articles Now Available
      • Long-Term Follow-Up Results Indicate Double Transplantation Is Superior To Single Transplantation For Myeloma
      • Beacon NewsFlashes – November 22, 2010
      • Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma
      • Beacon BreakingNews – Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma
      • Beacon NewsFlashes – November 17, 2010
      • Velcade May Increase Bone Formation In Multiple Myeloma Patients
      • Beacon SiteUpdate – Myeloma Beacon Launches Opinion Section
      • Beacon NewsFlashes – November 10, 2010
      • Growth Factor May Not Be Required Following Stem Cell Transplantation In Multiple Myeloma Patients
      • Multiple Myeloma Vaccine Shows Promise In Phase 1 Clinical Trial
      • Experts Publish Treatment Recommendations For Multiple Myeloma Patients With Kidney Impairment
      • Researchers Identify Factors Associated With Improved Survival In Myeloma Patients After Surgery For Skeletal Complications
      • Detection Of Rapidly Dividing Plasma Cells May Lead To More Targeted Treatment For Multiple Myeloma Patients
    • ► October (16)
      • Patients With Myeloma Precursor Disease MGUS May Have An Increased Risk Of Developing Blood Clots
      • Prolia May Delay The Onset Of Bone Complications More Effectively Than Zometa In Multiple Myeloma Patients
      • Velcade Maintenance Shows Little Improvement For Myeloma Patients Who Fail To Achieve Complete Response Post-Transplant
      • Beacon NewsFlashes – October 25, 2010
      • Lower Dose Of Aredia Is Equally Effective But Better Tolerated In Newly Diagnosed Multiple Myeloma Patients
      • Experts Assess Key Bone Proteins As Prognostic Tools For Multiple Myeloma And Myeloma-Related Bone Disease
      • Istodax Achieves Little Response In Refractory Multiple Myeloma
      • New FDA Warning About Bisphosphonates Does Not Apply To Multiple Myeloma
      • Personal Perspective: The Struggle Of Treating Multiple Myeloma In Turkey’s Centralized Health Care System
      • Itraconazole May Worsen Velcade-Induced Side Effects In Relapsed Multiple Myeloma Patients
      • ArthroCare Receives FDA Clearance For A New Device To Treat Spinal Fractures
      • Beacon NewsFlashes – October 8, 2010
      • Carfilzomib Application For FDA Approval Is Delayed
      • Caring For Someone With Multiple Myeloma – Part 3: The Toll Of Caregiving
      • Chinese Study Suggests That Velcade May Protect Against Blood Clots In Newly Diagnosed Multiple Myeloma Patients
      • Caring For Someone With Multiple Myeloma – Part 2: Practical Caregiving
    • ► September (14)
      • Caring For Someone With Multiple Myeloma – Part 1: Introduction To Being A Caregiver
      • Once-Weekly Velcade Is Equally Effective But Better Tolerated In Elderly Multiple Myeloma Patients
      • Beacon NewsFlashes – September 27, 2010
      • Velcade-Doxorubicin-Dexamethasone Treatment Can Reverse Kidney Damage Associated With Multiple Myeloma
      • Study Finds It Is Better To Dose Velcade After Melphalan Prior To Stem Cell Transplantation
      • Addition Of Velcade To Revlimid-Dexamethasone May Yield Better Prognosis For Myeloma Patients With Certain Chromosomal Abnormalities
      • Personal Perspective: Survivor Overcomes Multiple Myeloma And Amyloidosis
      • Multiple Myeloma-Associated Amyloidosis – What Every Patient Should Know
      • Long-Term Study Shows Thalidomide Delays Disease Progression In Smoldering Multiple Myeloma But Causes Significant Side Effects
      • Experts Recommend Against Donor Stem Cell Transplantation For Multiple Myeloma Patients Until Safety And Efficacy Is Improved
      • Cyclophosphamide, Low-Dose Thalidomide, And Dexamethasone Combination Is Safe And Effective For Multiple Myeloma Patients
      • Complete Response With Velcade-Melphalan-Prednisone Is Associated With Improved Outcomes In Newly Diagnosed Multiple Myeloma Patients
      • Beacon NewsFlashes – September 3, 2010
      • Guide To Nutrition In Multiple Myeloma – Part 2: Supplements
    • ► August (16)
      • Oral Busulfan Treatment May Be More Effective But Not As Safe As Melphalan Prior To Stem Cell Transplant In Multiple Myeloma Patients
      • NICE Recommends Thalidomide Over Velcade As First Line Treatment For Multiple Myeloma In The U.K.
      • Guide To Nutrition In Multiple Myeloma – Part 1: An Introduction
      • Velcade-Dexamethasone Therapy Improves Prognosis Of Multiple Myeloma Patients With The Chromosomal Abnormality t(4;14)
      • Personal Perspective: Tips For How Every Myeloma Patient Can Be Their Own Advocate
      • Etoposide Is Highly Effective For Stem Cell Mobilization In Multiple Myeloma Patients
      • Hycamtin-Cyclophosphamide-Melphalan May Be Effective And Safe For Multiple Myeloma Patients
      • MGUS And Smoldering Multiple Myeloma: Experts Identify Risk Factors For Disease Progression And Establish Monitoring Guidelines - Part 2: Smoldering Myeloma
      • Beacon NewsFlashes – August 18, 2010
      • MGUS And Smoldering Multiple Myeloma: Experts Identify Risk Factors For Disease Progression And Establish Monitoring Guidelines - Part 1: MGUS
      • Velcade May Not Be As Effective In Relapsed And Refractory Multiple Myeloma Patients With Duplications In Chromosome 1
      • Plitidepsin Is Not Very Effective For Multiple Myeloma But Merits Further Study In Combination With Other Treatments
      • Personal Perspective: Myeloma Patient Pays It Forward By Creating A Myeloma Support Group
      • Neurological Monitoring May Help Reduce Velcade-Induced Nerve Damage In Multiple Myeloma Patients
      • Combination Of Thalidomide And Cyclophosphamide May Negatively Impact Stem Cell Collection
      • New Four-Drug Combination May Be Effective And Safe In Newly Diagnosed Multiple Myeloma Patients
    • ► July (15)
      • Double Stem Cell Transplant With Low-Dose And High-Dose Melphalan Is An Effective Treatment For Multiple Myeloma
      • Higher Quality Response To Revlimid-Dexamethasone Combination Yields Better Prognosis For Relapsed And Refractory Multiple Myeloma Patients
      • Single-Agent Carfilzomib Continues To Show Promise For Relapsed And Refractory Multiple Myeloma
      • Thalidomide-Interferon Maintenance Therapy Increases Progression-Free Survival Time In Elderly Multiple Myeloma Patients
      • Beacon NewsFlashes - July 23, 2010
      • Bristol-Myers Squibb Halts Development of Tanespimycin
      • Research Shows No Difference Between Early And Later Treatment For Smoldering Multiple Myeloma
      • Heparin, Warfarin, And Aspirin Are Equally Effective In Preventing Blood Clots In Myeloma Patients Receiving Thalidomide (EHA 2010)
      • Abnormal Plasma Cells In The Blood May Indicate Aggressive And Treatment-Resistant Multiple Myeloma (EHA 2010)
      • Beacon NewsFlashes – July 14, 2010
      • Chromosomal Abnormalities May Predict Response To Initial Velcade-Based Myeloma Therapy (EHA 2010)
      • Study Reveals Common Features Of Long-Term Surviving Multiple Myeloma Patients (EHA 2010)
      • Donor Stem Cell Transplant Is Not More Effective Than Existing Treatments For Multiple Myeloma (EHA 2010)
      • Long-Term Thalidomide Treatment Improves Progression-Free Survival Of Myeloma Patients, But Does Not Extend Survival (EHA 2010)
      • Beacon NewsFlashes - July 1, 2010
    • ► June (27)
      • Multiple Myeloma Research Presented At 15th Annual European Hematology Association Meeting (EHA 2010)
      • Everolimus In Combination With Revlimid Shows Potential For Relapsed Multiple Myeloma (ASCO 2010)
      • Cyclophosphamide, Velcade, And Dexamethasone Combination Shows Promise For Newly Diagnosed Multiple Myeloma (ASCO 2010)
      • Guide To Clinical Trials For Multiple Myeloma Patients – Part 6: Phil’s Trial And Success
      • Panobinostat Combinations Show Therapeutic Benefit In Advanced Multiple Myeloma (ASCO 2010)
      • Zometa Increases Overall Survival And Slows Bone Disease In Multiple Myeloma Patients (ASCO 2010)
      • Beacon NewsFlashes – June 22, 2010
      • Elotuzumab Combinations Show Encouraging Results In Multiple Myeloma (ASCO 2010)
      • Guide To Clinical Trials For Multiple Myeloma Patients – Part 5: Don’s Trial And Success
      • Recent Advances In Treating Myeloma Bone Disease (ASCO 2010)
      • Addition Of Thalidomide To Standard Treatment For Elderly Multiple Myeloma Patients Increases Efficacy (ASCO 2010)
      • Treatment Of Myeloma With Novel Agents May Be As Effective As Stem Cell Transplantation – Part 2: Revlimid-Velcade-Dexamethasone (ASCO 2010)
      • Treatment Of Myeloma With Novel Agents May Be As Effective As Stem Cell Transplantation – Part 1: Melphalan-Prednisone-Revlimid (ASCO 2010)
      • Management Of Nerve Damage In Myeloma Patients (ASCO 2010)
      • Prevention Of Blood Clots In Myeloma Patients Is Important (ASCO 2010)
      • Carfilzomib May Benefit Relapsed And Refractory Multiple Myeloma Patients (ASCO 2010)
      • Reduced-Dose Velcade-Thalidomide-Dexamethasone Combination Shows Promise As Initial Therapy Prior To Stem Cell Transplantation (ASCO 2010)
      • Beacon NewsFlashes - June 11, 2010
      • Revlimid Maintenance Therapy Is Effective For Multiple Myeloma After Stem Cell Transplant (ASCO 2010)
      • ASCO 2010 Multiple Myeloma Update – Day Four
      • ASCO 2010 Multiple Myeloma Update – Day Three
      • Pomalidomide-Dexamethasone Combination Has Therapeutic Benefit For Heavily Pre-Treated Multiple Myeloma Patients (ASCO 2010)
      • ASCO 2010 Multiple Myeloma Update – Day Two
      • ASCO 2010 Multiple Myeloma Update - Day One
      • Carfilzomib-Revlimid-Dexamethasone Combination Is Well Tolerated As Longer-Term Multiple Myeloma Treatment (ASCO 2010)
      • Beacon NewsFlashes – June 4, 2010
      • German Translations Of Myeloma Beacon Articles Now Available
    • ► May (13)
      • Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 46th Annual Meeting (ASCO 2010)
      • Melphalan-Prednisone-Thalidomide Combination Shows Anti-Myeloma Effects But No Survival Benefit In Elderly Patients
      • Multiple Myeloma, Smoldering Multiple Myeloma, And MGUS May Be Linked To Osteoporosis
      • Guide To Clinical Trials For Multiple Myeloma Patients – Part 4: Selecting A Clinical Trial That Is Right For You
      • An Overview Of Myeloma Treatment Options In Europe – Part 4: Management Of Side Effects
      • Thalidomide-Dexamethasone Is Safe And Effective In Newly Diagnosed Myeloma Patients With Impaired Kidney Function
      • Beacon NewsFlashes – May 14, 2010
      • Guide To Clinical Trials For Multiple Myeloma Patients – Part 3: Myths And Facts About Clinical Trials
      • An Overview Of Myeloma Treatment Options In Europe – Part 3: Treatment Practices At Relapse
      • Suspended Resveratrol Clinical Trial: More Details Emerge
      • Zolinza-Velcade Combination May Be Effective In Relapsed/Refractory Myeloma
      • Resveratrol Trial In Multiple Myeloma Suspended Due To Safety Concerns
      • An Overview Of Myeloma Treatment Options In Europe – Part 2: First-Line Treatment Practices
    • ► April (15)
      • An Overview Of Myeloma Treatment Options In Europe – Part 1: Drug Availability
      • Elafin May Be Good Indicator Of A Common Stem Cell Transplant Complication
      • Beacon NewsFlashes – April 26, 2010
      • Guide To Clinical Trials For Multiple Myeloma Patients – Part 2: Benefits And Risks Of Clinical Trials
      • Follow-Up Results Confirm Survival Benefit Of Velcade-Melphalan-Prednisone Therapy in Multiple Myeloma Patients
      • Revlimid-Melphalan-Prednisone-Thalidomide Combination Is Effective And Safe In Relapsed/Refractory Myeloma
      • Causes Of And Treatments For Multiple Myeloma Drug-Induced Nerve Damage
      • Guide To Clinical Trials For Multiple Myeloma Patients – Part 1: Learning About Clinical Trials
      • New Guidelines For Managing Side Effects Of Thalidomide As Front-Line Myeloma Treatment
      • Beacon NewsFlashes – April 12, 2010
      • Personal Perspective: Cancer Inspires Multiple Myeloma Patient And Wife To Help Other Cancer Patients
      • Velcade-Doxorubicin-Dexamethasone Combination Followed By Thalidomide-Dexamethasone Is Safe And Effective In Relapsed/Refractory Multiple Myeloma
      • Velcade-Thalidomide-Dexamethasone Therapy After Stem Cell Transplant Improves Response In Multiple Myeloma Patients
      • Beacon NewsFlashes - April 5, 2010
      • Continuous, Low-Dose Cyclophosphamide And Prednisone Regimen Is Safe And Effective Salvage Treatment For Multiple Myeloma
    • ► March (16)
      • Study Shows Stable Multiple Myeloma Rates Over The Past 50 Years In Sweden
      • Short-Course Kepivance Reduces Mouth Ulcers After Stem Cell Transplant In Myeloma Patients
      • Beacon NewsFlashes - March 29, 2010
      • Non-Marrow Tumors Increase Among Myeloma Patients As Survival And Detection Methods Improve
      • Beacon NewsFlashes – March 23, 2010
      • Myeloma Beacon Launches New Myeloma Discussion Forums
      • Cyclophosphamide-Thalidomide-Dexamethasone Combination Is Promising As First Line Treatment For Myeloma Prior To Stem Cell Transplant
      • Velcade-Doxil-Dexamethasone Combination Is Effective And Safe In Elderly Myeloma Patients
      • Bone Lesions Detected By MRI Can Predict Progression Of Smoldering Myeloma
      • New Test Helps Predict More Specific Prognoses For Smoldering Myeloma Patients
      • Dose-Adjusted Revlimid-Dexamethasone Combination Is Safe And Effective In Multiple Myeloma Patients With Reduced Kidney Function
      • Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients
      • Beacon NewsFlashes – March 9, 2010
      • Study Documents The Impact Of Age At Diagnosis On Myeloma Patient Survival
      • Genetic Risk Factors And Treatment History May Predict Response In Patients With Relapsed/Refractory Myeloma
      • International Effort Updates Results From Multiple Myeloma Stem Cell Transplant Trials
    • ► February (15)
      • Thalidomide As Induction And Maintenance Therapy Improves Response Rates In Multiple Myeloma Patients
      • The Top Myeloma Research Of 2009
      • Achieving Very Good Partial Response Indicates A Good Prognosis For Multiple Myeloma Patients, Study Finds
      • Beacon NewsFlashes – February 18, 2010
      • Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence
      • Total Therapy Regimen May Be Highly Effective In Newly Diagnosed Myeloma Patients
      • Unresponsiveness To Revlimid Or Thalidomide Indicates Poor Response To Stem Cell Transplant, Study Finds
      • Revlimid Maintenance Therapy Is Added To Multiple Myeloma Treatment Guidelines
      • Revlimid-Cyclophosphamide-Prednisone Combination May Be Highly Effective For Refractory Multiple Myeloma Patients
      • Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds
      • Bone Formation And Degradation Proteins May Predict Progression Of Multiple Myeloma And Myeloma-Related Bone Disease
      • Beacon NewsFlashes – February 5, 2010
      • Addition Of Defibrotide To Melphalan-Prednisone-Thalidomide Combination Produces Fewer Side Effects In Multiple Myeloma Patients
      • Velcade-Doxil-Dexamethasone Regimen Followed By Post-Transplant Revlimid May Be A Highly Effective Treatment For Newly Diagnosed Myeloma Patients
      • Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
    • ► January (17)
      • Beacon NewsFlashes – January 29, 2009
      • Post-Transplant Revlimid Therapy Increases Complete Response Rates In Multiple Myeloma Patients, Study Finds (ASH 2009)
      • Despite Side Effects, High-Dose Melphalan Remains The Most Effective Dosage In Preparation For Stem Cell Transplantation
      • Velcade Induction and Maintenance Combinations Are Highly Effective In Elderly Multiple Myeloma Patients, Study Finds (ASH 2009)
      • Beacon NewsFlashes - January 25, 2010
      • Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study
      • Statins Reduce Acute Graft-Versus-Host Disease In Allogeneic Stem Cell Transplants, Study Finds
      • Study Compares Out-Of-Pocket Expenses For Myeloma Patients Treated With Velcade, Revlimid, Or Thalidomide (ASH 2009)
      • Beacon NewsFlashes – January 14, 2010
      • Thought Leader Perspective: Dr. Robert Kyle On Treating Multiple Myeloma
      • Celgene Plans To Seek Approval Of Revlimid As An Initial Treatment For Multiple Myeloma
      • M-CSF May Act As Powerful Prognostic Factor For Multiple Myeloma
      • Papayas, Papain and Multiple Myeloma: A Potential Adjunct Therapy That Requires Further Evaluation
      • FDA Approves Velcade’s Data Showing Survival Benefit In Newly Diagnosed Myeloma Patients
      • Revlimid May Be More Effective Than Thalidomide In Newly Diagnosed Multiple Myeloma
      • Elotuzumab In Combination With Revlimid And Dexamethasone Shows Encouraging Results In Multiple Myeloma (ASH 2009)
      • Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite Preventative Medication (ASH 2009)
  • ►2009 (269)
    • ► December (17)
      • Velcade-Thalidomide-Dexamethasone Treatment Is Promising For Newly Diagnosed Multiple Myeloma (ASH 2009)
      • Addition Of Thalidomide To Induction Therapy Increases Response Rates In Younger And Older Multiple Myeloma Patients (ASH 2009)
      • NPI-0052 Shows Promise In Relapsed/Refractory Multiple Myeloma (ASH 2009)
      • Novel Therapeutic Agents May Reduce Kidney Impairment In Newly Diagnosed Myeloma Patients (ASH 2009)
      • Preemptive Treatment Benefits High-Risk Smoldering Myeloma Patients, Study Finds (ASH 2009)
      • Revlimid Maintenance Therapy Significantly Extends Disease-Free Survival
      • Zolinza Combination Treatments Offer Benefit For Multiple Myeloma Patients (ASH 2009)
      • Perifosine Combination Therapy Is Promising For Relapsed And Refractory Multiple Myeloma (ASH 2009)
      • Revlimid May Set “New Standard” For Treating Newly Diagnosed Multiple Myeloma In Elderly Patients (ASH 2009)
      • Tanespimycin-Velcade Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
      • Survival Greater Than 10 Years In Multiple Myeloma Is Related To Longer Treatment Duration (ASH 2009)
      • Beacon NewsFlashes - December 8, 2009
      • Velcade-Dexamethasone Combination Regimen Increases Survival In Newly Diagnosed High Risk Myeloma Patients (ASH 2009)
      • Carfilzomib Is Effective For Multiple Myeloma – Part 2: Treatment Of Specific Patient Groups (ASH 2009)
      • Carfilzomib Is Effective For Multiple Myeloma – Part 1: As A Single Agent Or In A Combination Therapy (ASH 2009)
      • Beacon NewsFlashes - December 3, 2009
      • Velcade-Melphalan-Prednisone-Thalidomide (VMPT) Treatment Is Highly Active In Elderly Myeloma Patients (ASH 2009)
    • ► November (15)
      • Velcade-Torisel Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
      • Serum Albumin Levels Indicate Severity Of Multiple Myeloma
      • New Velcade Combination Therapy Effective For Newly Diagnosed Myeloma Patients (ASH 2009)
      • Treatment Trends For Multiple Myeloma – Part 3: Options For Elderly Multiple Myeloma Patients
      • Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)
      • Beacon NewsFlashes – November 23, 2009
      • Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
      • Myeloma Research To Be Presented At The American Society of Hematology’s 51st Annual Meeting (ASH 2009)
      • Vitamin C Inhibits Anti-Myeloma Activity Of Velcade
      • Beacon NewsFlashes – November 13, 2009
      • Treatment Trends For Multiple Myeloma – Part 2: Allogeneic Stem Cell Transplants
      • The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
      • Beacon NewsFlashes – November 6, 2009
      • Lawsuit Filed To Overturn Ban On Payment For Bone Marrow Donations
      • Treatment Trends For Multiple Myeloma – Part 1: Autologous Stem Cell Transplants
    • ► October (19)
      • Beacon NewsFlashes – October 30, 2009
      • Velcade-Doxil-Dexamethasone Combination Treatment Is Highly Effective In Newly Diagnosed Multiple Myeloma Patients
      • Thalidomide Improves Outcome Of Double Stem Cell Transplants In Younger Myeloma Patients
      • Study Shows Higher Survival With Revlimid And Low-Dose Dexamethasone Than Revlimid And High-Dose Dexamethasone In Multiple Myeloma Patients
      • Retreatment With Velcade As A Treatment Option For Relapsed Myeloma Patients
      • Phase 2 Clinical Trial Offers Positive Results For A Steroid-Free Multiple Myeloma Treatment
      • Beacon NewsFlashes – October 23, 2009
      • Study Shows Benefits Of Vesselplasty In The Treatment Of Spinal Fractures
      • New Recommendations Issued On Stem Cell Collection And Treatment With Revlimid, Thalidomide, And Velcade
      • Multiple Myeloma Study Finds Complete Response Is Generally Correlated With Survival
      • Myeloma Patients Are At Increased Risk For Blood Clots, Particularly Patients Using Revlimid Or Thalidomide
      • Beacon NewFlashes - October 15, 2009
      • Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
      • New Directory Could Assist In Myeloma Treatment
      • Beacon NewsFlashes – October 8, 2009
      • Carfilzomib Is Highly Active In Relapsed Myeloma Patients
      • Immune System Cells Protect Myeloma Cancer Cells, Study Finds
      • TIMP-1 Biomarker Predicts Myeloma Progression And Survival
      • Beacon NewsFlashes – October 2, 2009
    • ► September (19)
      • Taking Vitamin D And Calcium Supplements Together May Prevent Cancer
      • New Drug Enters Phase 2 Clinical Trial For Stem Cell Collection For Blood Cancer Patients
      • Second Dose Of Aloxi Further Reduces Chemotherapy-Induced Nausea In Cancer Patients
      • New Study Highlights Myeloma Treatment Infection Risks
      • Beacon NewsFlashes – September 23, 2009
      • Study On Myeloma Diagnosis Techniques Favors Newer Imaging Methods
      • Phase 3 Trial Indicates Denosumab Delays Skeletal Related Events In Cancer Patients
      • Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
      • Study Supports Use Of Kyphoplasty For Multiple Myeloma Patients
      • Beacon NewsFlashes – September 16, 2009
      • Swine Flu Vaccinations Recommended For Multiple Myeloma Patients
      • Beacon NewsFlashes – September 12, 2009
      • Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
      • Multiple Myeloma Conferences To Be Held In Hawaii, Arizona, Canada, And Greece
      • FDA To Review Velcade-Melphalan-Prednisone Regimen
      • Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients
      • Scientists Find A Protein That Causes Resistance To Velcade Treatment
      • Macrophages May Contribute To Survival Of Multiple Myeloma Cells
      • Beacon NewsFlashes – September 1, 2009
    • ► August (17)
      • Personal Perspective: Engineer With Myeloma Finds Hope Through Cancer Support Group And Blogs
      • Beacon NewsFlashes – August 27, 2009
      • Pathologic Fractures In Bisphosphonate-Treated Patients Not Indicative Of Myeloma Progression
      • Personal Perspective: The Adventures Of Cancer Girl
      • Eradicating H. pylori Infection Not Linked To MGUS Regression
      • Beacon NewsFlashes – August 20, 2009
      • Phase 1 Clinical Trial Studies Velcade And Zolinza In Myeloma Patients
      • Kidney Failure In Multiple Myeloma Patients - Part 4: Hemodialysis
      • Beacon NewsFlashes - August 14, 2009
      • Skipped Bone Marrow Exams Give False Positives In Multiple Myeloma Clinical Trials
      • Multiple Myeloma Vaccine Shows Promise In Mice
      • High Incidence Of Multiple Myeloma In World Trade Center Responders
      • Research Shows Velcade’s Possible Mechanism of Action
      • Shortage of Clinical Trial Participants Hinders War On Cancer
      • Beacon NewsFlashes – August 6, 2009
      • Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
      • Beacon NewsFlashes - August 3, 2009
    • ► July (20)
      • Study Shows Toxicity Of Second Transplant For Myeloma Patients
      • Clinical Trials Start For A Pre-Transplant Treatment
      • Researchers Sequence Full Multiple Myeloma Tumor Genome
      • Beacon NewsFlashes – July 28, 2009
      • Multiple Myeloma Patients’ Relatives Are Twice As Likely To Have MGUS
      • Dr. Sagar Lonial Provides Insight Into High-Risk Myeloma
      • Vitamin D Deficiency May Cause Skeletal Complications In Multiple Myeloma Patients
      • Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
      • Anti-DKK1 Antibody As New Treatment For Myeloma Bone Disease
      • Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
      • Beacon NewsFlashes – July 21, 2009
      • Kidney Failure In Multiple Myeloma Patients – Part 3: Time and Care Commitments
      • Dental Exams Recommended Before Bisphosphonate Therapy
      • Kidney Failure In Multiple Myeloma Patients - Part 2: Treatment
      • Beacon NewsFlashes -- July 14, 2009
      • Quality Of Life Warrants More Consideration In Multiple Myeloma Treatment Recommendations
      • Study Examines Quality Of Life After Stem Cell Transplantation
      • Beacon NewsFlashes – July 8, 2009
      • Vegetarians Less Likely To Develop Multiple Myeloma
      • Revlimid As Initial Myeloma Therapy Inhibits Stem Cell Collection
    • ► June (17)
      • Beacon NewsFlashes — June 30, 2009
      • Kidney Failure In Multiple Myeloma Patients - Part 1: Overview
      • XRCC5 Gene Variants Associated With Greater Blood Clot Risk During Thalidomide Treatment
      • Stem Cell Transplants May Improve Kidney Function of Myeloma Patients
      • Beacon NewsFlashes -- June 24, 2009
      • U.K. Finalizes Revlimid Therapy Guidelines
      • Canadian Authorities Confiscating Thalidomide At Border
      • Velcade Plus Dexamethasone Produces Robust, Yet Short-Lived, Response In Myeloma Patients
      • Beacon NewsFlashes - June 15, 2009
      • Revlimid Boosts Immune System Of Some Myeloma Patients
      • Beacon NewsFlashes - June 9, 2009
      • Study Shows Acute Kidney Failure Can Be Reversed By Velcade-Dexamethasone-Doxorubicin In Multiple Myeloma
      • Total Therapy Emerges As Prospect For Multiple Myeloma Cure
      • Myeloma Precursor MGUS Linked To Pesticide Use
      • Beacon NewsFlashes – June 3, 2009
      • Expert Panel Recommends European Approval Of Mozobil
      • Study Examines Romidepsin-Velcade Combination Treatment In Myeloma Patients (ASCO 2009)
    • ► May (23)
      • ONJ As A Prognostic Factor In Myeloma Patients Treated With Zometa (ASCO 2009)
      • Beacon NewsFlashes - May 29, 2009
      • Nexavar Shows No Effect In Phase 2 Study (ASCO 2009)
      • MMRF Announces Research Collaboration With The Broad Institute
      • Clinical Trial Shows Ginger Reduces Nausea (ASCO 2009)
      • New Hemodialysis Procedure Improves Health Of Multiple Myeloma Patients
      • IGF-1: An Important Myeloma Growth Factor
      • Trial Investigates Effects Of Tanespimycin-Velcade Combination Treatment (ASCO 2009)
      • Autologous Stem Cell Transplant Therapy With Velcade-Revlimid Or Velcade-Thalomid in New Multiple Myeloma Patients (ASCO 2009)
      • Phase 3 Study Shows High Response Rates For Four-Drug Combination (ASCO 2009)
      • Beacon NewsFlashes - May 18, 2009
      • Formaldehyde Exposure Linked To Increased Risk Of Multiple Myeloma
      • ASCO 2009 - 45th Meeting Of The American Society Of Clinical Oncology Only Two Weeks Away
      • Myeloma Patients In Canada Smuggle Low-Priced Thalidomide
      • Beacon NewsFlashes – May 13, 2009
      • Mozobil With Neupogen Increases Stem Cell Harvest Efficiency
      • Iowa Firefighters And Police Officers To Benefit From Cancer Bill
      • Durie-Salmon Staging System And International Staging System Compared In Patients After ASCT
      • Socioeconomic Standing May Affect Survival For Swedish Myeloma Patients
      • Beacon NewsFlashes – May 9, 2009
      • Current Use Of Velcade In Newly Diagnosed Myeloma Patients
      • Study Projects Rising Cancer Rates In The United States
      • New Hampshire Legislature Approves Medical Marijuana Bill
    • ► April (29)
      • Study Finds Lack Of Evidence For Link Between Firefighting And Cancer
      • Beacon NewsFlashes — April 28, 2009
      • The Access To Cancer Trials Act Of 2009 Brought Before Congress
      • Beacon NewsFlashes — April 27, 2009
      • NICE Recommends Revlimid For Multiple Myeloma Patients In U.K.
      • Melphalan-Prednisone Survival Rates Higher Than Thalidomide-Dexamethasone In Elderly
      • Study Measures Effects Of Novel Drugs On Myeloma Patients With Chromosomal Abnormalities
      • Beacon NewsFlashes – April 22, 2009
      • Long-Term Outcome Of Combination Auto/Allo Stem Cell Transplant Treatment Reported
      • Beacon NewsFlashes – April 20, 2009
      • Beacon NewsFlashes – April 17, 2009
      • New Revlimid Warning For Patients With Impaired Kidney Function
      • Gene Identification Could Lead To Better Treatment Options For Multiple Myeloma
      • High-Risk Myeloma Patients Show Overall Lower Progression-Free Survival With Revlimid-Dexamethosone Therapy
      • Thalidomide Plus Prednisone Shown To Improve Survival After ASCT
      • Beacon NewsFlashes – April 13, 2009
      • Beacon NewsFlashes – April 10, 2009
      • IMW 2009 - Physicians Debate "Cure Versus Control" Of Myeloma
      • IMW 2009 – Physicians Discuss Induction Therapy For Non-Transplant Candidates
      • IMW 2009 - Elotuzumab And Panobinostat Clinical Trials With Velcade
      • CMS Decides To Cover PET Scans For Myeloma Patients
      • Addition Of Salubrinal Could Dramatically Improve Velcade Response
      • Beacon NewsFlashes – April 7, 2009
      • Tools For Diagnosing Multiple Myeloma / Part 4: Specialized Studies
      • Growth In Off-Label Drug Use Slows
      • Blood Cancers Forum Focuses On Importance Of Clinical Trials
      • IMW 2009 – Physicians Discuss Upfront And Induction Therapy For Transplant Candidates
      • Beacon NewsFlashes – April 1, 2009
      • Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 2: Medicare-Approved Compendia
    • ► March (31)
      • New Gene Implicated In Multiple Myeloma And Other Cancers
      • Kennedy Renews War On Cancer
      • The MMRF Marathon And Half Marathon Program Seeks Runners
      • Beacon NewsFlashes – March 29, 2008
      • Beacon NewsFlashes - March 27, 2009
      • Genetic Blood Tests Could Soon Identify Multiple Myeloma And Other Disorders
      • Beacon NewsFlashes – March 25, 2009
      • Tools For Diagnosing Multiple Myeloma / Part 3: Prognostic Evaluation
      • Beacon NewsFlashes – March 23, 2009
      • Beacon NewsFlashes – March 21, 2009
      • Beacon NewsFlashes – March 20, 2009
      • Scotland Expected To Improve Patient Access To New Cancer Therapies
      • Beacon NewsFlashes - March 16, 2009
      • IMW 2009 - Physicians Discuss New Drugs For Relapsed/Refractory Patients
      • Beacon NewsFlashes - March 14, 2009
      • Tools For Diagnosing Multiple Myeloma / Part 2: End-Organ Damage Evaluation
      • New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
      • Current Information On Response Criteria For Multiple Myeloma
      • IMW 2009 - Physicians Discuss Symptom Management Strategies
      • Beacon NewsFlashes - March 10, 2009
      • Managing The Side Effects Of Revlimid And Velcade
      • Beacon NewsFlashes – March 9, 2009
      • Current Information On Risk Stratification In Multiple Myeloma
      • New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
      • Beacon NewsFlashes - March 6, 2009
      • IMW 2009 - Waldenstrom's Award Goes To IMF Co-Founder And Chairman
      • Blood Disorder MGUS Precedes Most Cases Of Multiple Myeloma
      • The MMRF Awards $1 Million For Promising Early-Stage Drug Development
      • Beacon NewsFlashes – March 2, 2009
      • IMW 2009 – Consensus On Risk Stratification In Multiple Myeloma
      • Beacon NewsFlashes - March 1, 2009
    • ► February (32)
      • Current Information On Staging Multiple Myeloma
      • New Myeloma Drugs Target Different Mechanisms Of Action: Cell Surface Receptors
      • Canadian Survey Highlights Myeloma Awareness And Access To Treatment
      • Beacon NewsFlashes - February 24, 2009
      • IMW 2009 - Physicians Offer Standardized Guidelines For Diagnosing Suspected Multiple Myeloma
      • Radiation Not Linked To MGUS Progression To Multiple Myeloma
      • Beacon NewsFlashes - February 23, 2009
      • IMW 2009 - Doctors Clarify Standards For Clinical Trial Reporting
      • Physicians Perform First Bone Marrow Transplant At Public Hospital In West Bengal, India
      • Health Care-Associated MRSA In Decline
      • XII International Myeloma Workshop Begins Next Week
      • Clarifications And Updates In Diagnosis Criteria Of Multiple Myeloma
      • Tools For Diagnosing Multiple Myeloma / Part 1: Diagnostic Evaluation
      • Beacon NewsFlashes - February 18, 2009
      • Bill Helps Oregon Firefighters Get Cancer Coverage
      • Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 1
      • MMRF And LLS Grant $500,000 For Study Of The Multiple Myeloma Stem Cell
      • The American Society Of Clinical Oncology Provides A Financial Guide To Cancer Care
      • Long-Term Survival Estimates Increase For Young Multiple Myeloma Patients
      • Researchers Identify Novel Tumor Feeding Mechanism
      • Beacon NewsFlashes - February 11, 2009
      • Beacon NewsFlashes - February 11, 2009
      • Leukemia & Lymphoma Society And Women’s Running Magazine Join Forces To Launch New Women’s Half Marathon
      • Regulations And The Rising Cost Of Cancer Drugs
      • MMRF Is The Official Charity Of The Rite Aid Cleveland 5K
      • Beacon NewsFlashes - February 6, 2009
      • Green Tea Blocks Effectiveness Of Velcade Treatment
      • Beacon NewsFlashes - February 4, 2009
      • Study Finds No Link Between Hair Dyes And Myeloma
      • Beacon NewsFlashes – February 2, 2009
      • Deal Brings Revlimid To U.K. Myeloma Patients
      • Beacon NewsFlashes - February 1, 2009
    • ► January (30)
      • Preventive Measures Can Reduce Osteonecrosis Of The Jaw In Patients Taking Zometa
      • Fruits And Vegetables Do Not Decrease Risk of Multiple Myeloma
      • Beacon NewsFlashes – January 28, 2008
      • FJC Awards $1 Million Grant To Institute For Myeloma And Bone Cancer Research
      • Blood Cancers The Subject Of Seminar At University Of Chicago Medical Center
      • Beacon NewsFlashes – January 26, 2009
      • Radiation Therapy, Vertebroplasty, And Kyphoplasty: Three Treatments For Myeloma Bone Disease
      • Scientists Develop Serum Immunoglobulin Free Light Chain Assay For Early Myeloma Diagnosis
      • Chemical Used In Rubber Synthesis Increases Risk Of Myeloma
      • New Drug for Preventing Nausea and Vomiting During Chemotherapy
      • Beacon NewsFlashes – January 21, 2009
      • MMRF Meeting Discusses Prognosis And Treatments For Myeloma Patients
      • Multiple Myeloma Treatment Approaches And Objectives
      • Phase 3 Zolinza-Velcade Trial Opening Soon
      • New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
      • Beacon NewsFlashes - January 19, 2009
      • Thalomide Approved For First-Line Treatments In Scotland
      • Treatment In Elderly Multiple Myeloma Patients
      • Tandem Autologous Stem Cell Transplantation Compared To Single Autologous Stem Cell Transplantation
      • Managing Steroid-Related Side Effects In Myeloma Patients
      • MMRF Meeting Discusses Racial Disparities In Multiple Myeloma
      • Novel Therapies For Myeloma Bone Disease
      • Beacon NewsFlashes – January 13, 2009
      • Bisphosphonate Treatment For Myeloma Bone Disease
      • Beacon NewsFlashes – January 9, 2009
      • Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
      • U.K. To Expand Access To Drugs For Terminally Sick
      • Anti-Cancer Drug Zolinza Shows Potential In Myeloma
      • Beacon NewsFlashes – January 5, 2009
      • Osteoporosis Drug Increases Risk Of Esophageal Cancer And Jaw Disease
  • ►2008 (65)
    • ► December (34)
      • Beacon NewsFlashes - December 30, 2008
      • Cancer Drugs To Cost More Under Medicare Plans
      • Leading Oncologists Present Clinical Research Advances in 2008
      • Clinical Trials Begin For New Form Of Radiotherapy
      • Skeletal Imaging For Bone Lesions In Multiple Myeloma Patients
      • ASH 2008 - New Induction Therapy for Elderly Patients
      • ASH 2008 - High Response Rate for Revlimid-Velcade-Dexamethasone Treatment in Phase 2 Studies
      • Diana Krall To Host Fundraiser Benefiting Blood Cancer Patients
      • FDA Approves Mozobil For Myeloma Patients Preparing For Stem Cell Transplants
      • Treatment In Young Multiple Myeloma Patients
      • ASH 2008 – Results Of Tandem Stem Cell Treatment For Newly Diagnosed Myeloma Patients
      • ASH 2008 - Ongoing Phase 2 Clinical Trials For Carfilzomib Show Promising Results
      • ASH 2008 - Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
      • ASH 2008 – Trial Results Compare Multiple Myeloma Transplantation Procedures
      • ASH 2008 – Venous Thrombotic Events In Newly Diagnosed Myeloma Patients Decrease Overall Survival
      • Beacon NewsFlashes - December 16, 2008
      • Impact of PET Scans Consistent Across All Types of Cancer
      • ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
      • Beacon NewsFlashes - December 12, 2008
      • ASH 2008 – Clinical Trial Update for Velcade-Thalidomide-Dexamethasone With Autologous Stem Cell Transplantation In Newly Diagnosed Myeloma Patients
      • Multiple Myeloma Research Consortium Announces Center Of The Year
      • ASH 2008 – Updated Velcade-Melphalan-Prednisone Trial Results For Newly Diagnosed Myeloma Patients
      • Deep Vein Thrombosis Risk Higher In Multiple Myeloma
      • ASH 2008 - VDD Initial Treatment More Effective Than TD Initial Treatment
      • ASH 2008 - Actimid-Dexamethasone Combination Highly Effective In Treating Relapsed And Refractory Multiple Myeloma
      • ASH 2008 - Scientists Reveal Promising Four-Drug Regimen For Newly-Diagnosed Myeloma Patients
      • Phase 3 Trials Of Hsp90 Inhibitors In Cancer Patients Underway
      • Outpatient Stem Cell Transplant For Multiple Myeloma
      • New Therapies Show Promise For Multiple Myeloma Treatment
      • Beacon NewsFlashes - December 5, 2008
      • Multiple Myeloma Survivors Honored At 2008 ASH Meeting
      • 50th Annual Meeting Of The American Society Of Hematology Only Days Away
      • Beacon NewsFlashes – December 2, 2008
      • Physicians Discuss Past Progress And Future Goals In Treating Multiple Myeloma
    • ► November (30)
      • Holiday Party In Las Vegas To Benefit The Leukemia & Lymphoma Society
      • Parade In New Zealand To Benefit Families Living With Multiple Myeloma
      • U.S. Cancer Incidence And Mortality Rates Fall For The First Time
      • Revlimid Combination Effective Against Relapsed And Refractory Myeloma
      • Beacon NewsFlashes - November 23, 2008
      • Increased Risk Of Blood Clotting Reported In Patients Treated With Avastin
      • IMF Continues Support Of Peter Boyle Memorial Fund
      • Long-Term Exposure To Benzene Appears To Increase Risk Of Multiple Myeloma
      • New Technique Shows Improved Detection Of Myeloma Tumor Cells After Treatment
      • IMF Announces New Global Research Partnership To Study Multiple Myeloma Biomarkers
      • Beacon NewsFlashes - November 17, 2008
      • Treatment With Folic Acid And B Vitamins Has Little Effect On Multiple Myeloma Risk Among Women
      • Beacon NewsFlashes - November 14, 2008
      • Link Between Gene Variation And Myeloma Survival
      • ImmunoCellular Therapeutics Presents Data Showing Immune Response On Cancer Stem Cells
      • Occupation And Chemical Exposure Linked To Multiple Myeloma
      • African-Americans Still At Higher Risk Of Developing Multiple Myeloma
      • Beacon NewsFlashes - November 11, 2008
      • CIGNA, Leukemia & Lymphoma Society Promote Financial Aid Program
      • Beacon NewsFlashes - November 7, 2008
      • International Myeloma Foundation Calls For Patient Access To Newest Myeloma Treatments
      • Beacon NewsFlashes – November 6, 2008
      • Antibody Treatment In Mice Shows Antitumor Activity
      • Prolexys Pharmaceuticals Raises $20 Million To Further Work On Anti-Tumor Molecule
      • Immune System Cells Show Promise As Multiple Myeloma Therapy
      • FDA Approves Cephalon's Treanda For Second Cancer Indication
      • MMRF Raises Over $1.5 Million In Annual Fall Gala
      • Incidence Of Multiple Myeloma In Women May Correlate With Height, Not Obesity
      • England And Wales May Halt Funding For Revlimid
      • Scientist Receives $720,000 Grant To Research New Multiple Myeloma Drug Targets
    • ► October (1)
      • A New Beacon For The Multiple Myeloma Community